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MASS SPECTROMETRY-BASED HIGHTHROUGHPUT APPROACH FOR
IDENTIFICATION OF MOLECULAR MODIFICATION OF OXIDATIVE
PROCESS IN RESPIRATORY DISEASES
WEI SONG
ABSTRACT

Eosinophil peroxidase (EPO) and myeloperoxidase (MPO) have been implicated
in generating reactive species and promoting oxidative modifications in numerous
diseases.

The detection and identification of potential pathways has been proven

extremely challenge due to evanescence nature of these reactive species. An alternative
approach to study the involvement of oxidative modification is to detect and quantify the
stable molecular fingerprints, like oxidized tyrosine species, in biological matrices.
Previously reported analytical methods for quantifying oxidized amino acids have
typically been limited by: low sensitivity, specificity and the failure of detection potential
oxidation products generated during sample handling. Using GC/MS in combination with
stable isotope dilution, a sensitive and self-quality control assay was developed. Using
this isotope-dilution GC/MS and multiple allergen challenge models, we demonstrate that
EPO is the major pathway for generating protein-bound 3-bromotyrosine in vivo.
However, the need for chemical derivatization of samples increases the possibility
that artifactual generation of oxidation products which may interfere with the detection of
native levels. Requirement of unique derivatization reagent for each oxidized tyrosine
results sample analysis both cumbersome and time/labor intensive.

Therefore, we

develop a liquid chromatography with on-line electrospray ionization tandem mass

iv

spectrometry (LC-ESI/MS/MS) assay that simultaneously detects and quantifies multiple
structurally informative protein oxidation products along with their precursor amino acids.
Use of four HPLC systems in multiplex array with column switching permits on-line
analyses of only relevant portions of chromatographic profiles and up to four-fold
increased throughput efficiency of mass detector usage.
Using this high-throughput multiplexed array-based LC-MS/MS method, we
found significant correlations among individual oxidized tyrosine in sera from healthy
volunteers.

These correlations provide chemical evidence that activated leukocytes

utilize various physiological available substrates to participate multiple oxidative
modifications in vivo.

In rhinosinusitis study, significantly elevated protein-bound

oxidized tyrosine species were detected in healthy nasal tissue compared to that at the
peripheral level.

In addition, rhinosinusitis patients had more severe oxidative

modification in their nasal tissue.

The evidence supports elevated bromination and

tyrosylation may contribute to the pathogenesis of rhinosinusitis.

v
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CHAPTER I
PEROXIDASE AND PEROXIDASE CATALYZED OXIDATIVE
DAMAGES

Peroxidases are heme-containing enzymes that catalyze the reduction of hydrogen
peroxide (H2O2) and facilitate the generation of various reactive species as part of the
innate host defense system

1-3

.

The mammalian peroxidase super-family includes

eosinophil peroxidase (EPO), lactoperoxidase (LPO), myeloperoxidase (MPO),
prostaglandin H1/2 synthases (PGHS-1, PGHS-2) and thyroid peroxidase (TPO) 4. The
major function of EPO and MPO is involved in protecting the host from infectious
diseases

5, 6

. Evidences indicate that EPO and MPO may also play a vital role in

facilitating oxidative modifications by generating reactive oxygen species in numerous
diseases such as asthma, rhinosinuositis, atherosclerosis and multiple sclerosis 7-9.
In this chapter, a brief review includes following topics: (1) Eosinophil peroxidase
(EPO) and myeloperoxidase (MPO); (2) Catalytic site of EPO and MPO; (3) Peroxidase
catalyzed oxidationand inflammatory diseases.

1

1.1

Eosinophil Peroxidase (EPO) and Myeloperoxidase (MPO)
Eosinophil peroxidase (EPO) and Myeloperoxidase (MPO) share a high degree

homology at genomic sequence level and in physiological function. Genetic studies
reveal that human EPO and human MPO are encoded by adjacent genes located on
human chromosome 17 4, 10. DNA sequence studies reveal that EPO and MPO gene both
contain 12 exons and 11 introns. Further, human EPO and human MPO have an overall
72.4% homology at nucleotide level and 69.8% homology at amino acids level

11

.

Elevated eosinophils, neutrophils and increased EPO, MPO contents are associated with
numerous disorder including allergic respiratory diseases, cardiovascular diseases and
neurodegenerative disorders

12, 13

. Upon stimulation, eosinophils and neutrophils are

recruited to the inflammation sites and release their specific granule proteins, including
peroxidases

14, 15

. Peroxidases utilize H2O2 and various substrates to generate cytotoxic

oxidants to fight invading pathogens 16, 17.
Genetic Properties of MPO and EPO
Genomic studies of MPO and EPO were started in the middle 1980s. Morishita et
al. used a synthetic 41-base oligonucleotide, which was decoded from amino acid
sequence of human myeloperoxidase, as a probe to isolate MPO cDNA clones from
human promyelocytic leukemia HL-60 cell. They identified a 2.6-kilobase nucleotide
that contained genetic information for a polypeptide which had 745 amino acids. The
calculated molecular weight was estimated of 83 kDa. Human MPO heavy chain was
located on the C terminus of this particular polypeptide.

18

. Yamada et al. isolated and

characterized a cDNA which encoded the carboxyl-terminal fragment of human MPO

2

heavy chain. Using this cDNA as a probe, they identified a MPO mRNA fragment with
approximately 3.3 kb in length.

In vitro translation of this MPO mRNA fragment

generated a major product, a 74 KDa polypeptide precursor.

The identity of this

polypeptide precursor was confirmed by co-precipitation with anti-MPO IgG antibody.
Antibodies specific for MPO light and heavy chains both recognized this polypeptide
precursor. These findings further support that MPO is initially synthesized as a single
polypeptide, and then it is further processed into a light chain and a heavy chain 19. Later,
human MPO mRNA was identified by MPO cDNA in human leukemia HL-60 cell.
Using in situ hybridization, Chang et al. located human MPO gene on chromosome
17q22-24

20

. Other studies also localize MPO gene to a region between 17q11-q21 and

17q21-q42 21. Interestingly, in mouse, the corresponding myeloperoxidase gene (mMPO)
was located on chromosome 1122.
Sakamaki et al. used northern hybridization and S1 mapping analysis of RNA
technique to confirm that EPO gene was only expressed in eosinophilic subline but not
neutrophilic subline or in parental human HL-60 cells 11. Using human MPO cDNA as a
probe, the chromosomal gene of human EPO was isolated and studied.

This gene

contained the genetic information for a polypeptide of 715 amino acids with an estimated
molecular weight about 81 KDa.

Further, EPO heavy chain and light chain were

identified at C and N termini of this polypeptide, respectively.

Later, In situ

hybridization studies indicated that human EPO gene was located on chromosome
17q23.1 23.

3

The high degree homology of human EPO and human MPO at genomic level
strongly supports the notion that both genes may originate from the same ancestral gene,
or from gene duplication and divergent evolution.
Biochemical Properties of MPO and EPO
Human myeloperoxidase (MPO, EC 1.11.1.7), a disulfide-linked dimer with two
light chains and two heavy chains, was purified from human leukocytes by three steps
including dialysis with a low salt buffer solution, separation by gel filtration
chromatography and carboxymethylcellulose chromatography. The molecular weight
(MW) of human MPO was estimated to be 118 kDa by sedimentation equilibrium
ultracentrifuge 24. A-Sepharose affinity chromatography was used to purify human MPO
from peripheral blood from one donor. The identity of extracted MPO was confirmed by
having maximum Soret absorbance at 430 nm. The MW of this human MPO was
estimated to be 146 KDa

25

. A rapid isolation procedure was applied to purify human

MPO from normal human leukocyte with about 17% yield. The high-spin heme signal in
this purified MPO was demonstrated by electron paramagnetic resonance spectroscopy
(EPR). The MW of this purified MPO was determined to be 144 KDa by ultracentrifuge
26

. A single polypeptide with MW of 80 KDa was identified as primary translation

product of MPO massager RNA (mRNA). Thise proMPO is formed by proteolytic
cleavage and N-linked glycosylation. After acquisition of heme group, the proMPO
undergoes a sequential of post-translational modifications to form mature MPO that
contains a pair of light and heavy chains 27 28.
Human eosinophil peroxidase (EPO, EC 1.11.1.7), a monomer with one light
chain and one heavy chain, was purified from eosinophilic leukemia cells by gel filtration

4

and ion-exchange chromatography.

The MW of EPO was determined by gel

chromatography and estimated to be 77 KDa. Sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) analysis revealed that this reduced EPO was composed
of one heavy chain and one light chain with MW of 52 KDa and 15 KDa, respectively 29.
Later, EPO was purified from normal leukocytes and also demonstrated similar molecular
weight of 72±1 KDa. Other analysis revealed this isolated EPO was composed by heavy
chain and light chain with MW of 58 and 14 KDa, respectively 30. Similar high spin EPR
signal of heme group was also observed in purified EPO 31. Radioimmunoassay revealed
that the content of EPO was estimated to be 15.0 μg/10 6eosinophils

29

. Carbon 14

labeled leucine was used as a probe to study the biosynthesis of EPO in marrow cells
from patients with eosinophilia. Two EPO precursors with MW of 78 and 72 KDa were
detected and recognized by anti-EPO antibody. Monensin, an inhibitor of MPO synthesis,
did not block the biosynthesis of EPO 32.
The major Soret band of oxidized MPO is observed at 430 nm and shifted to 470
nm after reduction 25. However, the major Soret band of purified EPO is observed at 412
nm 31. The unique distorted porphyrin ring structure and positive charged sulfonium ion
was observed in MPO. This distinctive structure of MPO is proposed to be the cause of
red shift of Soret band, and its distinct affinity for chloride. In site directed mutagenesis
studies indicate that the Soret band of MPO will shift back to 411 nm when the Met243 is
replaced by either of Thr, Gln or Val. The affinity for chloride is also decreased 100 fold
due to the replacement of Met243 in MPO 33.
Colorimetric assays are developed to determine peroxidase activity in biological
matrices.

MPO can specifically utilize chloride and hydrogen peroxide to oxidize

5

chromogen like tetramethylbenzidine (TMB) at pH 5.0 in the presence of resorcinol, an
EPO inhibitor

34, 35

. Other chromogens were used to measure MPO activity including

guaiacol, taurine and o-dianisidine dihydrochloride35-37. Unlike MPO, EPO oxidizes
bromide instead of chloride under physiological conditions to generate hypobromous acid
and its conjugate base hypobromite (HOBr/ OBr-) 38. EPO activity can be determined by
adding o-phenylene diamine at pH 8.0 in the presence of 3 mM bromide and 1 mM
hydrogen peroxide

34, 39

.

In all these approaches, measured peroxidase activity is

significantly affected by pH, the presence of peroxidase inhibitor, and the concentration
of chloride, hydrogen peroxide.
Immunochemical study indicates that the structure of EPO is distinct from that of
MPO. Antibodies that recognize human EPO do not cross react with human MPO, and
vice versa 32.
1.2

Catalytic Sites of MPO and EPO
Both MPO and EPO contain heme groups. The heme group contains an iron ion

(ferric oxidation state, Fe3+) at the center of protoporphyrin IX group. The ferric ion is
bound to four pyrrole nitrogen. The fifth coordination position is connected with a
histidine residue to form an imidazole side chain. The sixth position is believed to be
empty at the distal side of both native MPO and EPO. However, in MPO, histidine 95 at
distal side may perform as an acid/base catalyst to assist peroxidase catalyzed oxidation
40, 41

.
Low resolution X-ray crystallography (3 Å) study indicates that heme prosthetic

group of human MPO contains a bound calcium ion and three asparagine-linked
glycosylation. Around the heme prosthetic group, His336 is linked to the heme iron ion

6

on the proximal side of the heme in human MPO. Simultaneously, His336 is linked to
Asn421 through a hydrogen bond 42. Later, Fiedler et al. elucidated human MPO crystal
structure at higher resolution (1.8 Å) and demonstrated that the methyl groups on the
pyrrole rings A and C were covalently attached to the carboxyl groups of Glu242 and
Asp94, respectively, via ester bonds. The beta carbon of the vinyl group on pyrrole ring
A connects with the sulfur atom of Met243 to form a sulfonium ion linkage via a covalent
bond. Although the pyrrole ring B and D are still co-planar, ring A and C are bent to the
distal side. In addition, each side chain of Gln91, His95 and Arg239 connects with one
immobilized water molecule via a hydrogen bond. These three amino acids side chains
and the water molecules provide a solvent accessible environment and facilitate the
oxidation inside the catalytic site

43

. A similar covalent attachment in human EPO has

been identified. Glu241 is covalently attached with the pyrrole ring via an ester bond.
However, there is no sulfonium ion linkage in human EPO structure 44.
During the inflammation, MPO/EPO are secreted by activated leukocytes and
implicated in host defense. They play an essential role in oxidizing chloride (Cl-),
bromide (Br-), iodide (I-), and the thiocyanate (SCN-) to form strong oxidants that kill
microorganism as part of the defense function

7, 17, 45-47

. Three major intermediates, the

native state of MPO or EPO, Compound I and II are found to catalyze the generation of
these reactive oxidants,

40, 48, 49

. Each intermediate has its unique structure and spectral

property. Electron paramagnetic resonance (EPR) studies indicate the existence of a
ferryl/prophrin radical (Por˙+ FeIV=O) structure in MPO compound I (Cpd I) 41. Raman
resonance spectroscopy studies confirm the presence of oxyferryl (FeIV=O) structure in
MPO compound II (CpdII) 40

7

The structures of these intermediates and related reactions have been investigated
to understand the fundamental mechanism of peroxidase catalyzed oxidation. In the first
step of the catalytic cycle, H2O2 oxidizes native ferric form of MPO or EPO to
corresponding active state Cpd I by transferring two electrons and generating water
(Eq.1). Other in vitro studies indicate that other hydroxyperoxides like hypochlorous
acid (chloride-free media) can also oxidize native peroxidase to Compound I (Cpd I).
The reduction potential of Cpd I is about -1.1 V 50, 51.
PorFe3+ + H2O2

Por˙+FeIV=O + H2O

Æ

Eq.1

In the presence of endogenous one-electron donors like nitrite (NO2-), nitric oxide
(NO•) and tyrosine, Compound I can be quickly reduced to Compound II (Eq. 2), and
then further to the native ferric enzyme (Eq. 3) via obtaining two sequential one-electron
and generating nitro dioxide and tyrosyl radicals respectively

50, 52-54

. However, in the

presence of halides and thiocyanide (SCN-), compound I (Por˙+ FeIV=O) coverts to the
native form (Pro Fe3+) by obtaining two-electron reduction and generating the
corresponding hypohalous acid (Eq. 4).
˙+PorFeIV=O + R
PorFeIV=O + RH + H+
˙+PorFeIV=O + X- +H+

Æ PorFeIV=O + R˙

Eq. 2

Æ PorFe3+ + R˙ +˙ H2O

Eq. 3

Æ PorFeI3+ + HOX

Eq. 4

R= NO•, NO2-, Tyr, X= SCN-, Cl-, Br and IIn addition, researchers also propose the reactive species like H2O2, superoxide
can reduce native MPO to a ferrous intermediate (MPO-Fe2+).
Compound III (Cpd III, MPO-Fe

2+

An inactive state,

-O2) was formed via the binding between MPO-Fe 3+

8

and superoxide or MPO-Fe

2+

with oxygen, respectively

55-58

. It takes longer time for

Cpd III to be converted back to the native enzyme form which utilizes two H2O2
molecules and generate of one O2 molecule 56, 59. Studies support that Cpd III reacts with
57, 60

H2O2/ O2˙ to re-enter classical peroxidase cycle via Cpd II or native MPO
distinct spectroscopic measurement, our lab reported that both ferric (Fe
(Fe

. Using

3+

) and ferrous

2+

) MPO could reversibly bind to nitric oxide and generated stable low-spin six-

coordinate complexes Fe 3+ –NO and Fe 2+ –NO, respectively 51.
The scheme of catalytic cycles include three major pathways: (A) the conversions
of native ferric peroxidase (MPO) via Compound I, Compound II and back to the native
state of MPO; (B) the reaction of MPO (Fe

3+

) with superoxide or MPO (Fe

oxygen to generate compound III; (C) the reaction of MPO (Fe

3+

) or MPO (Fe

2+

) with

2+

) with

nitric oxide (Figure 1.1). Under certain condition, these reactions can be carried in the
opposite direction. Overall, the catalytic cycle of peroxidase starts with the conversion of
native enzyme to its active form Compound I by losing two electrons. Compound I can
be reduced to the native state (Fe3+) either by two-electron reduction or two sequential
one-electron reductions.

9

Figure 1. 1

Catalytic Cycles of MPO

The proposed MPO catalytic model: (A) Native MPO is converted to active MPO
Compound I (Cpd I) by losing two electrons. Compound I can be reduced to the native
state (Fe3+) either by two-electron reduction or to compound II (Cpd II) by a one-electron
reduction. The Compound II is further transformed to the native state via another oneelection reduction; (B) Native MPO (FeIII) or its reduced form MPO (FeII) bind with
superoxide or oxygen, respectively, to generate an inactive intermediate, compound III
(Cpd III); (C) Native MPO (FeIII) or its reduced form MPO (FeII) bind with nitric oxide
to form MPO (FeIII)-NO or MPO (FeII)-NO, respectively.

10

1.3

Peroxidases and Diseases
Both EPO and MPO are able to generate cytotoxic oxidants and cause the damage

of invading pathogens. However, these reactive oxidants may also associate with host
damage. Upon stimulation, eosinophils and neutrophils are recruited to the sites of
inflammation and release their unique granule proteins EPO and MPO, respectively.
EPO and MPO utilize H2O2 and available substrates to initiate a cascade of oxidative
events. In vitro studies demonstrate that MPO/EPO-H2O2-X- system are toxic to both
gram-negative and gram-positive bacteria

47, 61, 62

. The EPO-H2O2-X- system is capable

of killing parasites like Schistosoma Mansoni 63. The primary mechanism for EPO/MPO
to promote microbicidal function is based on the peroxidase catalyzed oxidative damage
to the pathogen. Microorganism like Schistosomula remains viable when it incubates
with EPO alone. The microbicidal function of peroxidase can be accomplished only in
the presence of hydrogen peroxide and halide 46, 63, 64. The cell injury can be inhibited by
adding heme-enzyme inhibitor, azide, which supports the catalytic role of the heme group
in the peroxidase 47.
The contribution of peroxidases in host defense has been questioned since the
majority of peroxidase-deficient subjects rarely suffer any severe infectious diseases.
Several reasons may attribute this scenario. First, most of these individuals only lost one
particular peroxidase activity, either MPO or EPO but not both

65, 66

.

The other

peroxidase-dependent or peroxidase-independent oxidants generation, may compensate
the loss of one particular peroxidase. In one unique case, a patient was both MPO and
EPO deficienct. He did suffere severe cor pulmonale disorder and one of his lungs was
completely damaged by the bacteria attack

67

11

. Second, infectious diseases like Candida

are predominately seen in MPO deficient patients with diabetes mellitus

68

. Utilizing

GC/MS and LC/MS/MS, Brennan et al investigated the potential pathways that
participate the generation of 3-nitrotyrosine generation in vivo.

Within multiple

inflammation models, the formation of 3-nitrotyrosine were evaluated in EPO or MPO
wild type and knockout mice. In some models, MPO or EPO played a dominant role,
accounting for the majority of nitrotyrosine generation. However, in other leukocyte-rich
acute inflammatory models, no significant protein-bound nitration was observed

69

.

Overall, peroxidase does play an important role in host defense against bacteria, fungi
and parasites infection.
Other than the beneficial effects of peroxidases in host defense, more and more
evidence indicates that peroxidase catalyzed oxidation may lead to host damage. Recent
studies indicate that eosinophils and eosinophil peroxidase may involve in the
pathogenesis of allergic respiratory diseases like asthma, rhinosinusitis by promoting
oxidative modification 9, 70, 71.
Asthma, a common lung disorder in developed countries, is characterized by
wheezing, breathlessness, chest tightness and coughing with reversible airway
obstruction. In 1998, an estimate of 17 millions Americans suffered from this lung
disorder. In addition, 30% of these patients were children 72. Similarly, rhinosinusitis is
an inflammation disease characterized by nasal congestion, itching, sneezing and nasal
discharge. In 2001, an estimate of 58 millions Americans suffered rhinosinusitis 73. The
overall direct cost of asthma and chronic rhinosinusitis is estimated over $ 10 billion per
year 72, 74.

12

Eosinophil infiltration and activation are associated with airway allergic responses.
First, eosinophilia is predominately observed in asthma and rhinosinusitis patients.
Significantly elevated eosinophils were observed in peripheral blood, and sputum
recovered from asthmatic patients

70, 71, 75

In rhinosinusitis patients, even if they had

negative skin response, elevated eosinophils were detected in peripheral blood and in
nasal lavage fluids (NLF)

12, 76

. It is still not clear whether this eosinophilia in patients

who suffer respiratory disorder just an epi-phenomenon of allergic disease or a
representation of the involvement of eosinophil in the inflammation response. A house
mite allergen challenge study was performed in asthmatic subjects and healthy controls.
Bronchoalveolar lavage (BAL) was collected 6 hours after allergen challenge.
Significantly elevated eosinophils recovered from BAL fluid were observed in asthmatic
patients compared to that in the healthy controls in response to the allergen challenge.
This finding supports that eosinophils are actively recruited to the lung as a consequence
of allergen provocation 13.
In response to cytokine and chemokine stimulation, eosinophils release bioactive
molecules, generate reactive species and initiate oxidative modification. Eosinophils are
recruited to the inflammation sites and release eosinophil specific granule proteins in
response to chemokines stimulation

77, 78

.

Chemokines cooperate with cytokines to

stimulate eosinophil differentiation, activate cellular response and amplify the immune
responses

78-80

.

Activated eosinophils releases unique granule proteins including

eosinophil cationic protein (ECP), eosinophil peroxidase (EPO) and major basic protein
(MBP), and stimulates peripheral mast cell to release histamine
MBP activates neutrophils, basophils and mast cells

13

83, 84

.

81, 82

. Further, isolated

In addition, activated

eosinophils release lipids mediator including PAF, LTC4/D4/E4

85-87

. These bioactive

lipids initiate the allergic response by contracting smooth muscle, increasing mucous
secretion and facilitating granulocytes migration. The details and references are tabulated
in Table 1.1.
Peroxidases are the principle enzymes that generate reactive species in allergic
diseases like asthma and rhinosinusitis.

In the presence of hydrogen peroxide and

physiological halide, EPO but not other eosinophil basic granule proteins can cause
human lung injuries halides

46

. Eosinophil peroxidase can specifically oxidize bromide

even in the presence of 1000 fold higher chloride condition

38

. In aeroallergen lung

challenge model, compared to peroxynitrite catalyzed tyrosine nitration, EPO- H2O2NO2- system is more efficient in generating nitrotyrosine in vivo. After allergen challenge,
70% elevated 3-nitrotyroine in EPO+/+ animal is originated from EPO-H2O2-NO2- 69.

14

Table 1.1

Bioactive Molecules Detected in Asthmatic Patients

Chemokines

Abbreviation

Reference

Regulated upon Activation Normal T-cell

RANTES

70, 77, 78, 88-90

Expressed and Secreted
Macrophage Inflammatory Protein-1α

MIP-1α

Interleukin-8

IL-8

Cytokines
Tumor Necrosis Factor-alpha

TNF-α,

Tumor Necrosis Factor-beta

TNF -β

Interleukin-3

IL-3,

Interleukin-5

IL-5,

Granulocyte-macrophage Colony-

GM-CSF

15, 89, 91

78-80, 92-94

stimulating Factor
Platelet-derived Growth Factor-β

PDGF-β

Vascular Endothelial Growth Factor

VEGF

95, 96

Granule Cationic Proteins
Eosinophil Cationic Protein

ECP

Eosinophil Derived Neurotoxin

EDN

Eosinophil Peroxidase

EPO

Major Basic Protein

MBP

9, 76, 81-84, 97-99

Lipid mediators
Leukotriene-C4/ D4/ E4

LTC4/ D4/ E4

Platelet Activating Factor

PAF

Prostaglandin E2

PGE2

15

15, 70, 85-87, 100, 101

Aromatic amino acid like tyrosine is readily oxidized by peroxidase by losing the
phenolic hydrogen and one electron to form tyrosyl radical (Y˙)

102

. Tyrosyl radical is

relative stable since the radical delocalize around the aromatic ring. The tyrosyl radical
reacts with free or protein bound tyrosyl residue to form dityrosine. EPO and MPO
utilize hydrogen peroxide and various physiological substrates to generate corresponding
reactive bromating species (RBS), reactive chlorinating species (RCS), and reactive
nitrogen species (RNS) species, catalyze oxidative modification and participate airway
remodeling 2, 103-105 (Figure 1.2).
Peroxidase catalyzed oxidative modification is proposed to implicate in the
pathogenesis of respiratory disease like asthma and rhinosinusitis.

Several clinical

studies support that the release of EPO during inflammation response results in extensive
oxidation. After a localized allergen challenge, 3-bromotyrosine content recovered from
BAL was increased 10-fold, but there were only two- to threefold increases in 3chlorotyrosine in the mild asthmatics

104

. Aldridge et al. found that protein-bound 3-

Bromotyrosine, recovered in sputum from asthmatic patients, was significantly elevated.
The levels of this bromination product correlated highly positively with eosinophil
peroxidase protein mass (r = 0.79, p< 0.0001)

106

. In addition, 10-fold increase in

protein-bound 3-nitrotyrosine, and 100-fold increase in protein bound 3-bromotyrosine
were recovered from BAL of severe asthmatics compared to that from healthy control 107.
Indeed, peroxidase catalyzed oxidation is implicated in promoting oxidative tissue
modification in allergic respiratory diseases.
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Figure 1. 2

Potential Enzymatic Pathways for Generating Reactive Oxidants and

Oxidation Products
Each reactive oxidant may result oxidative damage and contribute inflammatory
injury. NOS NO synthase, iNOS inducible NO synthase, M2+, redox-active metal ion, Pr
(M2+), protein-bound redox-active metal ion, L-Arg, L-Arginine.
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CHAPTER II
METHODS FOR ANALYSIS OF OXIDIZED TYROSINE SPECIES

Peroxidase catalyzed oxidative modifications are implicated in various
physiological

and

pathological

neurodegenerative disorders

1-3

.

processing

like

aging,

allergic

response

and

Both in vitro and in vivo studies support reactive

intermediates generated by MPO/EPO reacting with a variety of targets including protein,
lipid and genetic materials

4-9

. It is extremely important to understand the operational

mechanisms of peroxidase induced oxidation because it may not only provide
information on the involvement of oxidative modification in disease development, but
may also offer insights into possible strategies to slow or stop oxidative modification.
Reliable analytical techniques are needed to detect and quantify those reactive
species including reactive brominating species (RBS), reactive chlorinating species
(RCS) and reactive nitrogen species (RNS).

However, it is extreme challenges to

monitor the generation and reaction of these reactive intermediates in vivo due to the
transient nature of these reactive intermediates. As an alternative approach, most studies
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are focused on detecting and quantifying stable end-products of each distinct oxidative
pathway from normal and pathological specimens4-9.

Protein oxidation has been

intensively investigated since the last decade due to the following reasons: (1) protein is
the major scavenger of oxidative free radical species both in intra and extra cellular
environments 1; (2) protein has a longer half-time compared with other macromolecules
and may preserve more structural changes

10

; (3) the modification on the protein may

associate with the change of the corresponding enzymatic function and may initiate a
cascade biological event

1, 11, 12

. Although various amino acid residues are subjected to

reactive oxygen species attack, aromatic amino acid residues like tyrosine, phenylalanine
and tryptophan are more vulnerable to free radical induced oxidation

13, 14

For example,

3-Bromotyrosine can be generated by the reaction of tyrosine with HOBr/OBr- which
may originate from the EPO/MPO-H2O2-Br- system

15

. 3-Chlorotyrosine is the product

of tyrosine reacting with HOCl/OCl- or with species such as chlorine (Cl2)

16, 17

.

3-Nitrotyrosine is generated when reactive nitrogen species react with free tyrosine or
tyrosine residue

6, 7, 18

. Dityrosine is formed by radical-radical addition reaction via a

tyrosyl radical generating system

19, 20

.

Hydroxyl radical oxidizes phenylalanine to

generate non physiologic tyrosine species, m-tyrosine and o-tyrosine

13, 21

. All these

oxidized tyrosine species resist to change during acid hydrolysis. Indeed, these oxidized
tyrosine species are unique molecular fingerprint to study potential the mechanisms of
protein oxidation.
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2.1

Antibody-based Immunostaining and ELISA Assays
A variety of approaches including immunohistochemical and enzyme-linked

immunosorbent assay (ELISA) have been developed by using commercially available
polyclonal and/or monoclonal antibodies to recognize oxidized tyrosine species.
Antibodies which specifically recognized oxidized tyrosine species including 3nitrotyrosine, Dityrosine, 3-chlorotyrosine have been used to detect and localize these
oxidation markers in vivo 22-27.
Immunostaining offers a way of localizing oxidized tyrosine species within
biological matrices

28

.

Using 3-nitrotyrosine (3-NO2Y) specific antibody and

immunohistochemical staining, elevated 3-NO2Y was detected in myocardium from
patients with myocarditis 23, in atherosclerotic lesions of human coronary arteries 29, 30, in
the lower neuron from multiple sclerosis patients

31

suffered Alzheimer's disease or Parkinson’s disease

, in Lewy body core from patients
32, 33

patients with adult respiratory distress syndrome (ARDS)
detected in lipofuscin from aged human brain

24

and in the lung tissue from
34

. Similarly, dityrosine was

. In the mice endotoxemia model,

3-Chlorotyrosine was detected in liver tissue and co-localized with neutrophils 27.
ELISA assay is a powerful tool to evaluate relative amounts of oxidized tyrosine
species in vivo.

Detection of oxidized tyrosine residue requires minimum sample

handling procedures including incubation, washing and reaction. In addition, there is no
artifact generation during sample processing and the oxidized protein remains intact and
may use for further investigation. Using an ELISA assay, 3-nitrotyrosine was only
detected in plasma from type II diabetic patients (n= 40, 0.251±0.141 μM) 35. Elevated

35

3-nitrotyrosine (1.27±1.03 μM) was detected in plasma samples from celiac disease
patients but not in that from controls

36 37

. Recently, several studies reported using

competitive enzyme-linked immunosorbent assay (c-ELISA) to quantify nitrated protein
in plasma and other biological fluids

38, 39

. Other studies reported the detection of 3-

nitrotyrosine residue in various matrixes including bovine serum albumin (BSA), human
serum albumin (HSA), α1-antiprotease inhibitor, pepsinogen and fibrinogen. To quantify
nitrated protein, a standard curve was constructed by determining the binding of the anti3-NO2Y antibody to the immobilized antigen (nitrated protein) in the presence of a serial
dilution of nitrated BSA or corresponding nitrated protein solutions (Fig 2.1). Their
assay demonstrates the high affinity between 3-NO2Y residue and polyclonal antibody.
95.8% antibody binding was inhibited by 10 mM of 3-NO2Y but only 3.3% inhibition
was observed in the presence of the 10 mM of tyrosine. But the specificity of this assay
may be challenged due to the extremely low abundance of 3-NO2Y compared with
tyrosine (3-NO2Y:Y, approximately 0.1-1:106)40. In addition, the high affinity binding
between antibody and 3-NO2Y residue may also be altered by the environment of 3NO2Y residue, distinct protein structure, sample amount, and other components that may
cross react with the antibody. The half maximal inhibition concentration (IC50) values for
different nitrated protein were varied from 5-100 nM 41.

36

1
Figure 2. 1

2

3

Schematic Diagram of Competitive ELISA

Nitrated BSA (immobilized antigen);
protein in sample;

nitrated BSA (standard) or nitrated

Rabbit anti-nitrotyrosine IgG;

HRP conjugated donkey anti-

rabbit Ig G. Briefly, the 96-well plate was blocked with nitrated BSA. A PBS solution
containing polyclonal rabbit anti-nitrotyrosine Ig G was mixed with variable amount of
nitrated BSA and incubated with immobilized nitrated BSA. The rabbit anti-nitrotyrosine
Ig G was bound with either immobilized nitrated BSA or nitrated BSA in PBS solution.
After a sequential washing, incubating donkey anti-rabbit Ig G antibody was applied to
bind with rabbit anti-nitrotyrosine Ig G which was bound with immobilized nitrated BSA.
After washing, distinct color was developed and detected at 490 nm.
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However, cross-reactivity and semi-quantitative nature dramatically limits the
utilization of this technique for quantification purpose

38, 41

. Although the antibodies

were developed to target a distinct oxidized tyrosine residue, the abilities of these
antibodies to specifically recognize this unique oxidation product, especially in complex
biological matrixes, were little tested. The identity of recognized antigen may be queried
because there is no direct structural information of this antigen available in the assay.
Further more, there is no immunochemical assay yet available that can simultaneously
quantify multiple oxidized tyrosine species and their precursors.
2.2

Analytical-based Quantitative Assays
Analytical approaches include sample extraction, separation, and quantification of

the protein-bound oxidized tyrosine species. High performance liquid chromatography
(HPLC) and gas chromatography (GC) are commonly used to separate oxidized tyrosine
species in the protein hydrolysate

2, 8, 15-18, 20, 42-45

. Detection techniques can be selected

based on the requirement for selectivity, precision and detection limit. Currently, on-line
detectors include ultraviolet-visible detector (UV), fluorescence detector, electrochemical
detection detector (ECD) and mass spectrometer (MS).
2.2.1

Protein Hydrolysis
Peroxidase catalyzed oxidation generate both free and protein bound oxidized

tyrosine species.

To analyzing protein-bound oxidized tyrosine species, protein is

separated from salts and hydrolyzed into amino acid residues. Protein was commonly
hydrolyzed to yield free amino acids under 6 M HCl at 110 ◦C for about 24 hours

46-48

.

Further investigations indicate that tyrosine can be easily nitrated when co-incubate with
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trace amount of nitrite or nitrate ions in acidic condition at elevated temperature

40, 49

.

Trace amount of nitrite ion (10 μM) induces significant tyrosine nitration (up to 250 fold
increase). However, this nitration can be significantly reduced by adding 1% phenol or
1% butylated hydroxytoluene (BHT) into this acidic system

50, 51

.

Similar tyrosine

chlorination and bromination were noticed in acidic condition in the presence of the
corresponding anion ions, chloride and bromide, respectively 15, 52.
Several approaches are carried out to eliminate potential artifacts generation during
protein hydrolysis. First, all the glassware should be carefully cleaned to create a clean
environment (nitrite, nitrate, chloride and bromide free). The general procedure includes
rinsing with HPLC grade water, and baking at 500 degree over 12 hours to reduce the
anions

17, 52

. Second, techniques including dialysis, protein precipitation and strong

cation ion exchange chromatography, are used to separate protein from water soluble
salts prior to acidic hydrolysis

52-54

. Third, oxidation scavengers including phenol and

BHT are added into the system to reduce artifact generation 50. Finally multiple protein
hydrolysis techniques are developed to meet individual purpose. For example,
hydrobromic acid (HBr) or methanesulfonic acid (MSA) instead of hydrochloric acid is
used to eliminate chloride ion in system

2, 17

.

Mild enzymatic digestion in neutral

condition (pH=7.2) was performed and no artifact was detected

40, 50

. However, the

potential limitations of enzymatic digestion include low yield of protein hydrolysis and
the contribution of tyrosine and oxidized tyrosine species from autolysis of protease itself
49, 50

.

Alkaline hydrolysis also demonstrated that no artifact was generated during

processing. However, multiple interference peaks of 3-nitrotyrosine were observed and
additional derivatization step (acidic condition) was required

39

55

.

In addition, the

degradation of oxidized tyrosine species was observed during alkaline hydrolysis

56, 57

.

Although these procedures were proved effectively reduced tyrosine residue oxidation
during hydrolysis, none of these methods can guarantee no artifact generation during
protein hydrolysis. To monitor the artifact generation, unique isotope labeled tyrosine
species (13C9, 15N1 Tyr and 2H4 Tyr respectively) were added prior to protein hydrolysis
and served as chemical detectors of preparative oxidation

18 55

. Compared to the natural

abundance tyrosine, the isotope labeled tyrosine species are structurally identical except
for the extra molecular weight. During sample preparation, if trace amount anion ions are
left in the hydrolysis chamber, natural abundance tyrosine (12C9,

14

N1 Tyr) and the

corresponding isotope labeled tyrosine (13C9, 15N1 Tyr or 2H4 Tyr) will be oxidized at the
same reaction rate to generate distinct oxidation products which can be distinguished by
the mass spectrometer only 18, 52, 55. In deed, isotope labeled tyrosine serves as an internal
quality controller for potential ex vivo oxidized tyrosine generation to insure that the final
result only represents oxidation stress in vivo.
2.2.2

Sample Purification and Derivatization
Due to the complexity of biological matrixes, purification and derivatization are

essential steps for quantification of free or protein-bound tyrosine species. Purification is
used to remove extra acid, salt and unwanted debris from biological matrix.
Derivatization is a critical step that can modify the structure of analyte to get better
separation and sensitivity.
Protein precipitation (PPT), liquid-liquid extraction (LLE) and solid phase
extraction (SPE) are commonly used to desalt and to remove macromolecules and
potential interference substances.

Organic solvents like acetonitrile, chloroform,

40

methanol and diethyl ether were used to isolate protein in tissue homogenate, plasma, and
other biological fluids

18, 40, 52, 55

. Protein dissolves in solvent with large dielectric

constant like water. Organic solvents with smaller dielectric constant, like acetonitrile
and methanol, significantly decrease protein solubility and induce protein precipitation 58.
The smaller the dielectric constant of the final solution, the lower solubility of the protein
will be. In addition, decreased temperature also facilitates protein precipitation. Protein
pellet is obtained by centrifuging at 4000~9000 g

55 18

. The supernatant (for free amino

acid) or protein pellet (for protein bound amino acid residue) are recovered.
Liquid-liquid extraction (LLE) is a powerful tool to separate an analyte from a
mixture or to remove unwanted interference compounds. The separation is achieved
based on the difference in solubility of the analyte in two immiscible liquid phases
(aqueous phase and organic phase). The more hydrophobic of the analyte, the better
extraction efficiency is achieved by LLE.

Extracted analyte is easily recovered by

separating the liquid layer. The extraction efficiency of analyte (E) is determined by
equation 2.1:

E=

KD V
1 +KD V

2.1

KD is the partition coefficient of the analyte in the organic and aqueous phases (Co/Caq);
V is the volume ratio of two phases (Vo/Vaq). To get better extraction efficiency, the
organic solvent is selected with bigger KD value and larger volume. Successive multiple
extractions give a better recovery. Using chloroform as the extraction reagent, about
93% of the free dityrosine was extracted from cerebrospinal fluid 59. Other reagents like
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mixture of chloroform/methanol (v:v, 2:1) were used to extract 3-nitrotyrosine from
human plasma 55.
Solid phase extraction (SPE) is commonly used to remove water soluble strong
acid/base. The 3 mL SPE cartridge with 100-500 mg packing material was commonly
used. The packing material of SPE column is often in irregular shape with diameters
above 50 μm (10-20 fold larger than HPLC packing material).

The separation

mechanism of SPE is similar to that of HPLC column. First the analyte is loaded on a
pre-conditioned cartridge. The analytes and unwanted debris are separated by choosing
appropriate washing and eluting solvents. The eluted analytes are analyzed directly or
dried under vacuum and then reconstituted prior to quantitation. Compared with LLE,
SPE demonstrates a better separation of analyte from interferences, easier collection of
analyte fraction and less organic solvent usage. In addition, automation can easily be
adapted using SPE column.

Different adsorbents, extraction mechanism were

investigated to improve the recovery and eliminate interference peak of analytes in
different matrices.

In addition, different washing, elution solvents were compared.

Reverse phase C-18 SPE column is one of the commonly used cartridges to remove
excess acid and potential debris in protein hydrolysate

6, 17, 18, 43, 45, 52, 60

.

Further

purification is achieved by using additional chrom P cartridge right after C-18 SPE
extraction

61

.

Frost et al used a polymeric resin based ENV+ cartridge to remove

interference of 3-nitrotyrosine

55

. Anion exchange column (AG1-XS8) was used to

purify 3-nitrotyroisne in protein hydrolysate

62

.

Tandem octadecylsilyl and

aminopropylsilyl cartridges were applied to isolate tyrosine and nitrotyrosine respectively

42

in protein hydrolysate

63

. Aminopropyl cartridge was used to isolate dityrosine, ortho-

tyrosine and nitrotyrosine in cat urine 64.
Derivatization is a method of chemically transforming the analyte into a new
compound which has different volatility, thermo-stability and better chromatographic
behavior to fit the requirement of quantitation 65. For GC based assay, the derivatization
step is an essential step to eliminate the presence of polar group like OH, NH2 and
COOH.

The carboxylic acid group (COOH) of tyrosine and oxidized tyrosine are

converted to the corresponding ester derivative by reacting with 1-propanol at acidic
condition (HCl or HBr) at 65 ◦C for 20~ 30 minutes

2, 52

. The resulting solutions further

react with heptafluorobutyric anhydride (HFBA), pentafluoropropionic anhydride (PFPA)
and trifluoroacetic anhydride (TFAA) in the presence of ethyl acetate 52 2, 51. N-(t-butyldimethylsilyl)-N-methyltrifluoroacetamide chlorosilane (TBDMS) was used to protect
hydroxyl group to form an ether derivative

55

.

However several steps including

acetylation, o-deacetylation and reduction were required to achieve a better separation
and lower detection limit 40. The complexity of derivatization procedures may introduce
potential artifacts generation, especially under acidic conditions

49

.

Chemical

derivatization of analyte prior to HPLC system gave a lower detection limit and better
chromatographic behavior.

Butylation of o-tyrosine and nitrotyrosine dramatically

improved their sensitivity. MS response of o-tyrosine and nitrotyrosine were increased 7
and 6 fold respectively. However, butylation of o,o'-dityrosine did not improve the
sensitivity due to the side reactions. The limit of quantitation (LOQ) of NO2-Tyr butyl
ester, o-Tyr butyl ester, and di-Tyr in cat urine samples were reported at 14.5, 28.2 and
140.9 nM, respectively 64.
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2.3

HPLC with on-line Ultraviolet-visible and Fluorescence Detector

HPLC is a common technique for separation. A number of LC detectors including
ultraviolet-visible (UV), fluorescence detector, electrochemical detector (ECD) and mass
spectrometer (MS) are developed to accomplish different requirements. Both UV and
fluorescence detectors have been used to quantify free oxidized tyrosine species based on
specific absorbance at acidic or basic condition.
Using an UV detector, Kaur et al. detected 3-nitrotyrosine in serum and synovial
fluid from rheumatoid arthritis patients but not in that from controls. Later, this method
was adopted to determine plasma level 3-nitrotyrosine in chronic renal failure patients 66.
A higher plasma level of 3-nitrotyrosine was detected in patients with septic shock (173.9
μM) than those without shock (75.6 μM). In addition, no 3-nitrotyrosine was detected in
control plasma. The detection limits were reported to be 0.2 -0.6 μM

66, 67

. Protein-

bound nitrotyrosine was detected based on its characteristic spectral absorbance in
alkaline or acidic solutions.

After treated with peroxynitrite or tetranitromethane,

oxidized bovine Cu-Zn superoxide dismutase have a maxima absorbance at 438 nm in
basic solution (pH 9.5) and a secondary peak at 356 nm in acidic condition (pH 3.5) 7.
After exposure to a 100-fold molar excess of peroxintirite, glutathione reductase also
exhibits absorbance at approximately 423 nm, indicating the presence of 3-Nitrotyrosine
residue

68

. Using HPLC with online UV detector (280 nm, pH=2.5), Wu et al reported

the generation of 3-bromotyrosine and 3,5-dibromotyrosine by incubating HOBr or Nbromo, or N,N-dibromoamine with 2 mM tyrosine solution 15.
Using pre-column derivatization techniques, the amino groups of 3-nitrotyrosine or
dityrosine are reacted with fluorescence active compounds including 7-fluoro-4-

44

nitrobenzo-2-oxa-1, 3-diazole, o-phthalaldehyde and 4'-Dimethylaminoazobenzene-4sulfonyl chloride. The derivatized tyrosine species can be detected by the fluorescence
detector

69, 70

. The detection limits of these assays were reported at 0.1-1 pmol level.

Compared to the UV detection, fluorescence detection has lower background, better the
sensitivity and selectivity. But these two approaches are limited for identification of any
ex vivo generated trace level oxidized tyrosine species during sample preparation.
2.4

HPLC with On-line Electrochemical Detector

Electrochemical detector (ECD) was widely applied to detect and quantified 3nitrotyrosine

71, 72

, 3- Chlorotyrosine

73

, dityrosine

74

, meta- and ortho-tyrosine

75, 76

. A

better selectivity and lower detection limit is achieved by combining HPLC separation
system and sensitive electrochemical detector.
Using HPLC-ECD system, 3-nitrotyrosine was detected by passing through
reduction potential and then following oxidation potential. Elevated plasma level 3nitrotyrosine was observed after lipopolysaccharide (LPS) administration 71. Hensley et
al reported an assay using ECD detector to quantify tyrosine, 3-nitrotyrosine and 3,4dihydroxyphenylalanine (3,4-Dopa) simultaneously

77

. Later, they observed elevated

dityrosine and 3-nitrotyrosine in the hippocampus and neocortical regions of the brain
and ventricular cerebrospinal fluid form Alzheimer patient compared to that from healthy
control 72.
To achieve a lower detection limit, 3-nitrotyrosine was modified to N-acetylamino-tyrosine before loading HPLC-ECD system. The separation was significantly
improved after 3-nitrotyrosine acetylation, o-deacetylation and reduction. In addition, the
detection limit was reported at 20 fmol 40, 50. Other assays used ECD detector to quantify
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3-chlorotyrosine, dityrosine, meta-tyrosine and ortho-tyrosine generated in vitro and in
vivo 73-76.
2.5

Mass Spectrometry-based Assay

Mass spectrometry (MS) is a powerful analytical technique that is widely used for
identification, quantitation and clarification of structural properties of interested
analyte(s). Mass spectrometer is divided into three major parts: ionization chamber (ion
source), ion analyzer and detector (Fig 2.2). Once the sample is introduced into an
ionization chamber, the gas phase cation or anion ions are generated. The resulting ions
are separated in the mass analyzer according to their mass charge ratio (m/z). Once the
ion which contains selected m/z ratio reaches the detector, an electronic signal will be
generated and recorded by the data system. Compared with other LC detector, mass
spectrometer is more expensive, less user friendly. But unique selectivity and sensitivity
of mass spectrometry offer an ability to quickly detect and quantify interested compound
which only require minimal sample preparation, even for complex biological matrix like
tissue homogenate, plasma etc78.
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GC
Ionization
Chamber

LC

Mass Analyzer

Detector

CE, etc.

Figure 2. 2

Schematic Diagram of Mass Spectrometer

Analytes are introduced into ionization chamber by several separation techniques
including gas chromatography (GC), liquid chromatography (LC), and capillary
electrophoresis (CE). Once cation (positive) or anion (negative) ions were generated in
ionization chamber, these ions were transported into ion analyzer and sorted according
their m/z ratios. Only the ion with correct m/z ratio can pass through the ion analyzer and
reach the detector.
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Various ionization techniques, including electron impact (EI), chemical ionization
(CI), negative-ion chemical ionization (NICI) electrospray ionization (ESI) and
atmospheric pressure chemical ionization (APCI), may be used to detect and quantify
biomarkers like oxidized tyrosine species

62, 79-83

. In electron impact (EI) ionization

mode, the high-energy electron (~70 ev) is generate from electrically heated filament.
Then the high-energy electrons collide with gas phase analyte. One electron from neutral
molecule (A) is knocked out, and the positive charge ion (A+) is generated.

This

ionization process may generate either molecular ion (A+) or fragment ions (B+ or C+)
dependent on applied electron energy, source temperature and the structure of the analyte,
(Equation 2.2).
A + e

Æ A+ + 2e

A + e Æ B+ + C+ + 3e

(Eq.2.2)

Later chemical ionization (CI), a softer ionization technique, was adopted for
quantitation of 3-nitrotyrosine. The CI technique starts with reagent gas being ionized by
electron impact ionization. Then the electronic charge is transferred from reagent gas ion
to the gas phase analyte molecule through ion-molecule reaction to generate analyte ion.
Negative-ion chemical ionization (NICI) is similar to CI technique. However, the reagent
gas serves as the buffer gas to slow down the high-energy electrons so that some
electrons have just the right energy to be captured by analyte molecules.
Atmospheric pressure ionization (API), the ionization technique that occurs under
atmospheric pressure (760 mm Hg), includes electrospray ionization (ESI), atmospheric
pressure chemical ionization (APCI) and atmospheric pressure photo ionization (APPI).
The first two ionization techniques, ESI and APCI, are more commonly used in detection

48

and quantitation of polar molecules like oxidized tyrosine species

84

. In electrospray

ionization (ESI), analyte solution is pushed through a narrow charged capillary interface
and sprayed as very fine mist of charged droplets. Warm high purity nitrogen flow is
commonly used to facilitate liquid evaporation. As a consequence of evaporation, the
droplet surface charge density is increased.

A phenomenon referred as Coulombic

Fission is occurred and the gas phase ion is generated. ESI works well for polar, charged
compounds with small and large molecular weights. Multiple charge ions are commonly
observed in ESI spectrum. Atmospheric pressure chemical ionization (APCI) is more
frequently used to anlayze less-polar compound. The sample solution is heated and
sprayed with high flow rate nitrogen to form aerosol mist. The corona discharge needle
is used to ionize the analyte. Compared with ESI, APCI is essentially a gas-phase
ionization technique.
Numerous of mass analyzers are developed to accommodate the requirements on
mass range, accuracy and precision.

Magnetic sector mass spectrometer (double-

focusing mass spectrometer) provides high sensitivity and resolution by separating of
ions based on their passages through the perpendicular electric and magnetic fields.
Time-of-flight (TOF) mass spectrometer measures the time that is required for the
accelerate analyte ions to pass through a constant length tube. It provides a moderate
mass resolution over a larger mass range. Ion trap mass spectrometer retains ions into a
small region (ion trap) between a ring electrode and two end cap electrodes by specific
oscillating electronic field. By changing the potential on the end caps, the ions within a
specific m/z range can be trapped in or ejected out of the ion trap. Ion trap mass
spectrometer is widely used because of its ability of performing a sequential MS/MS

49

reaction modes to provide valuable structure information 85. However, Quadrupole mass
spectrometer is the most commonly used mass spectrometer for quantitation purpose.
Quadrupole mass spectrometer contains four parallel cylindrical rods that surround the
ion paths. Radio-frequency (RF) voltage and direct current (DC) voltage are applied on
the quadrupole rods to permit the ion with particular m/z ratio passing through this
electronic field. Only the selected ion with specific m/z ratio has a stable trajectory and
reaches the detector. Other ions with different m/z ratios have unstable oscillations that
increase in amplitude until they collide with quadrupole rods 86 87.
As mentioned previously, both single and triple quadrupole mass spectrometers are
widely used for quantitation of oxidized tyrosine species. A schematic diagram of a
typical triple quadrupole mass spectrometer is presented in figure 2.3.

A triple

quadrupole mass spectrometer includes of three quadrupoles. The system includes two
mass filters (the first and third quadrupole, Q1 and Q3 respectively) and a collision cell
(the second quadrupole, Q2). Triple quadrupole can be operated in different modes
including Q1 scan (Q1), single ion monitoring (SIM), parent ion scan, daughter ion scan,
neutral loss and multiple reaction monitoring (MRM) to accommodate analysis
requirement. In Q1 scan (Q1), Q1 is set at a scan mode, which allows Q1 to filter one m/z
each time sequentially. For triple quadrupole, both Q2 and Q3 are set at standby mode and
there is no collision-activated dissociation (CAD) gas present in Q2. Thereby the ion
passes through Q2 and Q3 directly and reach detector to generate the corresponding
signal. Q1 scan provides the mass spectra in a specific mass range. Q1 scan is commonly
used to determine the m/z ratio of molecular ion due to the limitation of low sensitivity.
In single ion monitoring (SIM) mode, Q1 is set to monitor one target ion with specific
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m/z ratio and both Q2 and Q3 are set in standby mode. Only ion with specific m/z ratio
can pass through quadrupole (Q1) and reach the detector.

SIM mode detects and

quantifies one particular ion, which dramatically improve the sensitivity. Since only the
ion with selected m/z ratio can pass through Q1, the background noise is significantly
decreased. In parent scan mode, Q1 operates in scanning mode and transmits ion with
sequential m/z ratio into the collision cell (Q2). When the ions enter Q2, they collide with
the neutral CAD gas molecules and generate corresponding fragment ions.

The

fragmented ions (daughter ions) are then transported to Q3, which is set at SIM mode for
the daughter ion with particular m/z ratio. Similarly, in daughter scan mode, Q1 is set at
SIM mode to isolate one particular ion (parent ion). After the collision in Q2 cell, the
corresponding fragmented ions (daughter ions) are transported to Q3. The Q3 operates in
scanning mode and filters each distinct m/z ratio successively. The resulting daughter
spectrum of the selected parent ion provides valuable structure information. Daughter
scan provides potential ion pair transitions that may be used in MRM mode. Neutral loss
is applied to identify compounds that lost a specific uncharged group during either a
rearrangement process or collision induced dissociation (CID). In neutral loss mode,
both Q1 and Q3 operate in scanning modes with the particular difference (∆m). The
detector responses to the ion that loss (or gain for neutral gain) the selected uncharged
group (∆m) in Q2. Multiple reaction monitoring (MRM) is designed to detect and
quantify a specific analyte in complex matrices. In MRM mode, both Q1 and Q3 are set
at SIM mode. The ion with specific m/z ratio is isolated by Q1 first. Then this parent ion
is collided with CAD gas in Q2 cell and generated corresponding daughter ion (s). Only
selected daughter ion(s) can pass through Q3 and reach the detector. Both SIM and MRM
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mode are widely used in quantitation of oxidized tyrosine species due to their exceptional
sensitivity. Compared with SIM mode, MRM is more sensitive and provides better
specificity.
In current mass spectrometer, the detector generates electronic current which is
proportional to the mass abundance of each specific m/z ratio. Commonly used ion
detectors include electron multiplier, photomultiplier, Faraday cup and microchannel
plate detector 87.
2.6

Analytical Methods of Quantitation of Oxidized Tyrosine Species

Numerous assays based on gas chromatography with on-line mass spectrometer
(GC/MS or GC/MS/MS) were developed to analyze oxidized tyrosine level at
physiological and pathological conditions. GC/MS offers better separation and higher
sensitivity. One limitation of GC/MS technique is that all the analytes has to be the gas
phase prior to separation and detection. To analyze polar compounds like oxidized
tyrosine species by GC/MS system, various chemical derivatization reagents were
employed to increase analyses’ volatility and ionization efficiency 88 6, 16, 17, 43-45.
Using GC combined stable isotope dilution mass spectrometry, the detection limit
of 3-Chlorotyrosine was 50 attomole with coefficients of variance (CV) within 3% 52. 3chlorotyrosine was detected in normal aortic intima. The level of 3-chlorotyroisne was
30-fold higher in LDL isolated from atherosclerotic intima than that from circulating
LDL

16

. A fully validated GC/MS/MS assay was developed to detect and quantify 3-

nitrotyrosine in human plasma. The internal standard was purified by HPLC to eliminate
nitrate and nitrite to avoid artifacts generation during sample preparation. Using this
technique, basal level 3-nitrotyrosine was determined in 11 healthy volunteers
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Figure 2. 3

Schematic Diagram of Typical Triple-quadrupole Mass Spectrometer

and Its Operation Modes

Typical triple-quadrupole includes two mass filters Q1 and Q3 and one collision cell
Q2. Numerous modes including Q1 san, SIM, parent scan, daughter scan, MRM and
neutral loss can be achieved by adjusting individual quadrupole setting (detail see table).
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100-fold elevated dityrosine was observed in LDL isolated atherosclerotic lesions
compared to the circulating LDL. No similar increase of meta-tyrosine or ortho-tyrosine
was detected 43. Dityrosine and ortho-tyrosine were also detected in mouse heart, muscle,
brain, liver and urine sample

44, 45

. At basal level, 3-bromotyrosine in bronchoalveolar

lavage (BAL) proteins recovered from mildly allergic asthmatic individuals was slightly
higher than that from controls. After a localized allergen challenge, in BAL protein, 3bromotyrosine content was increased 10-fold, but only two- to threefold increases in 3chlorotyrosine 2.
In these studies, the accuracy and sensitivity were significantly improved by
utilizing isotope labeled internal standard (13C labeled or
combining multiple reaction monitoring mode (MRM),

2

88, 90

H labeled isotopmer)

.. HPLC with on-line

electrospray ionization mass spectrometry or tandem mass spectrometry (HPLC/ESI/MS
or HPLC/ESI/MS/MS) assay has several advantages compared with GC/MS assay.
Chemical derivatization procedure becomes an optional step to improve sensitivity. But
majority LC/MS assay skip this step to eliminate the potential sample loss, contamination
and side reactions 79. Sample preparation is dramatically simplified and the efficiency is
significantly improved 88.
LC/MS/MS assays for detecting oxidized tyrosine species in different matrices
were explored.

A simple and sensitive LC/MS/MS assay was used to detect 3-

nitrotyrosine in rat brain tissue. The detection limit was below 10 nM81.

Free 3-

nitrotyrosine, 3-bromotyrosine and 3-chlorotyrosine were detected in plasma from
healthy volunteers 79. Yi et al. developed a LC/MS/MS assay to detect and quantify 3nitrotyrosine and tyrosine simultaneously. HPLC condition was optimized to detect 3-
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nitrotyrosine even in presence of 100,000-fold higher tyrosine. The detection limit for
standard samples was 0.5 pg/μL (s/n>3) with a linear range from 0.5-100 pg/μL 49. After
peroxynitrite treatment, 3-nitrotyrosine and 3, 5-dinitrotyrosine were observed in peptides
like leucine-enkephalin (YGGFL), V3 loop (GPGRAF), and LVV-hemorphin7
(LVVYPWTQRF) 91.
Protein bound dityrosine in milk powder was analyzed by LC-ESI/MS/MS. The
mean recovery of dityrosine from milk powder was about 90%. The limit of detection
(LOD) and limit of quantitation (LOQ) for protein bound dityrosine (diTyr/Tyr) were set
at 2 μmol/mol and at 6 μmol/mol 92.
HPLC combined atmospheric pressure chemical ionization-tandem mass
spectrometry (HPLC-APCI-MS/MS) system was also utilized to detect tyrosine,
dityrosine, simultaneously. The linearity of each analyte was larger than 0.98. The limits
of quantitation (LOQ) of tyrosine, dityrosine, in human urine sample were 1 μM, 50 nM,
respectively 82.
Other applications include detecting plasma level 3-nitrotyrosine and 3chlorotyrosine in preterm infants with clinically documented bronchopulmonary
dysplasia 93 Significantly elevated 3-Bromotyrosine was detected in sputum supernatants
recovered from mild to moderate asthma compared to that from controls. But no
significant increase of protein bound 3-chlorotyrosine and carbonyl were observed
between two groups

94

. Elevated protein bound 3-chlorotyrosine also were recovered

from tracheal aspirate in low weight infants (n=69) compared to the controls with regular
weight. In addition, these 3-chlorotyrosine levels were strongly correlated with
myeloperoxidase activity (r 2= 0.75, p < 0.0001)
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95

.

Using HPLC-MS/MS, 3-

chlorotyrosine was detected in HDL recovered from human aortic atherosclerotic lesion
96

. Also elevated dityrosine was detected by LC/MS in brain of Alzheimer’s disease

(AD) patients 97.
2.7

Conclusions

To further understand the mechanism of EPO/MPO induced oxidative damage both
in vitro and in vivo, the level of an array of oxidized tyrosine species and their precursors

need carefully investigate. GC/MS, LC/MS and LC/MS/MS are highly sensitive and
specific approaches to study these oxidation products in biological specimens. Mass
spectrometer provides specific structure information of each analyte.

Compared to

antibody based immunochemical assay, mass spectrometry based assay has a better
sensitivity and specificity.

Overall GC or LC/MS/MS approach is superior to

immunochemical methods and other chemical detection approaches by providing specific
structural information, improved sensitivity and simplicity of sample preparation.
Here we demonstrate the unique character of mass spectrometry based assay to
quantify multiple oxidized tyrosine species in various biological specimen. First, it can
simultaneously detect and quantify six oxidized tyrosine species and the corresponding
precursors. As illustrated in figure 1.2, activated eosinophil and neutrophil releases its
unique granule protein EPO and MPO, respectively. EPO or MPO utilizes hydrogen
peroxide and various physiological substrates to generate corresponding reactive
bromating species (RBS), reactive chlorinating species (RCS), and reactive nitrogen
species (RNS) species. These reactive species participate in oxidative modification and
involve in inflammatory injury. To study the operational mechanism of EPO and MPO
catalyzed oxidative modification, multiple oxidative products are investigated to re-
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construct the oxidative damage in vivo. Other GC/MS and LC/MS assays can only detect
one or several oxidized tyrosine species. To obtain the over all oxidation products,
several assays are required. In our assay, detection and quantitation of multiple analytes
is achieved by multiple-channel monitoring. It quantifies six oxidized tyrosine species
and the corresponding precursors simultaneously, which provides a snapshot of EPO or
MPO induced oxidative stress in vivo.
Second, unique isotope-labeled internal standards were used to insure the quality of
data. The preparation lost was calibrated by adding the isotopically labeled internal
standard. [13C6] ring isotopically labeled oxidized tyrosine and universally labeled
tyrosine, phenylalanine (i.e. all carbons

13

C, all nitrogen

15

N) as the internal standard

prior to protein hydrolysis. Unique universally labeled oxidized tyrosine species serve
internal quality control to monitor artifact generation. Multiple distinct natural abundance
oxidized tyrosine species were identified and quantified by the corresponding [13C6] ring
labeled isotopomer, while simultaneously the ions possessing the anticipated m/z
transitions for universally labeled oxidized amino acids were monitored as an indicator of
the generation of preparative oxidation products.
Finally these mass spectrometry based approaches can be used to detect oxidized
tyrosine species and their precursors, tyrosine and phenylalanine respectively, in different
biological matrices including plasma, BAL, CSF and tissue.

High sensitivity and

reproducibility ensures that our assay is a powerful tool to explore the free radical
induced oxidation in vivo.

These unique properties suggest protein-bound oxidized

residues can serve as molecular probes to identify the underlying oxidation pathways in
diseases like atherosclerosis and cancer.

57

2.8

Reference:

1.

Stadtman, E. R., Protein oxidation and aging. Science 1992, 257, (5074), 1220-4.

2.

Wu, W.; Samoszuk, M. K.; Comhair, S. A.; Thomassen, M. J.; Farver, C. F.;
Dweik, R. A.; Kavuru, M. S.; Erzurum, S. C.; Hazen, S. L., Eosinophils generate
brominating oxidants in allergen-induced asthma. J Clin Invest 2000, 105, (10),
1455-63.

3.

Brennan, M.; Gaur, A.; Pahuja, A.; Lusis, A. J.; Reynolds, W. F., Mice lacking
myeloperoxidase are more susceptible to experimental autoimmune
encephalomyelitis. J Neuroimmunol 2001, 112, (1-2), 97-105.

4.

Shen, Z.; Wu, W.; Hazen, S. L., Activated leukocytes oxidatively damage DNA,
RNA, and the nucleotide pool through halide-dependent formation of hydroxyl
radical. Biochemistry 2000, 39, (18), 5474-82.

5.

Shen, Z.; Mitra, S. N.; Wu, W.; Chen, Y.; Yang, Y.; Qin, J.; Hazen, S. L.,
Eosinophil peroxidase catalyzes bromination of free nucleosides and doublestranded DNA. Biochemistry 2001, 40, (7), 2041-51.

6.

Wu, W.; Chen, Y.; Hazen, S. L., Eosinophil peroxidase nitrates protein tyrosyl
residues. Implications for oxidative damage by nitrating intermediates in
eosinophilic inflammatory disorders. J Biol Chem 1999, 274, (36), 25933-44.

7.

Ischiropoulos, H.; Zhu, L.; Chen, J.; Tsai, M.; Martin, J. C.; Smith, C. D.;
Beckman, J. S., Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide
dismutase. Arch Biochem Biophys 1992, 298, (2), 431-7.

58

8.

Zhang, R.; Brennan, M. L.; Shen, Z.; MacPherson, J. C.; Schmitt, D.; Molenda, C.
E.; Hazen, S. L., Myeloperoxidase functions as a major enzymatic catalyst for
initiation of lipid peroxidation at sites of inflammation. J Biol Chem 2002, 277,
(48), 46116-22.

9.

Agosti, J. M.; Altman, L. C.; Ayars, G. H.; Loegering, D. A.; Gleich, G. J.;
Klebanoff, S. J., The injurious effect of eosinophil peroxidase, hydrogen peroxide,
and halides on pneumocytes in vitro. J Allergy Clin Immunol 1987, 79, (3), 496504.

10.

Gebicki, S.; Gebicki, J. M., Formation of peroxides in amino acids and proteins
exposed to oxygen free radicals. Biochem J 1993, 289 (Pt 3), 743-9.

11.

Dean, R. T.; Fu, S.; Stocker, R.; Davies, M. J., Biochemistry and pathology of
radical-mediated protein oxidation. Biochem J 1997, 324 (Pt 1), 1-18.

12.

Marquez, L. A.; Dunford, H. B., Kinetics of oxidation of tyrosine and dityrosine
by myeloperoxidase compounds I and II. Implications for lipoprotein peroxidation
studies. J Biol Chem 1995, 270, (51), 30434-40.

13.

Maskos, Z.; Rush, J. D.; Koppenol, W. H., The hydroxylation of phenylalanine
and tyrosine: a comparison with salicylate and tryptophan. Arch Biochem
Biophys 1992, 296, (2), 521-9.

14.

Sarchielli, P.; Galli, F.; Floridi, A.; Gallai, V., Relevance of protein nitration in
brain injury: a key pathophysiological mechanism in neurodegenerative,
autoimmune, or inflammatory CNS diseases and stroke. Amino Acids 2003, 25,
(3-4), 427-36.

59

15.

Wu, W.; Chen, Y.; d'Avignon, A.; Hazen, S. L., 3-Bromotyrosine and 3,5dibromotyrosine are major products of protein oxidation by eosinophil peroxidase:
potential markers for eosinophil-dependent tissue injury in vivo. Biochemistry
1999, 38, (12), 3538-48.

16.

Hazen, S. L.; Heinecke, J. W., 3-Chlorotyrosine, a specific marker of
myeloperoxidase-catalyzed oxidation, is markedly elevated in low density
lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997, 99, (9),
2075-81.

17.

Hazen, S. L.; Hsu, F. F.; Mueller, D. M.; Crowley, J. R.; Heinecke, J. W., Human
neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest
1996, 98, (6), 1283-9.

18.

Brennan, M. L.; Wu, W.; Fu, X.; Shen, Z.; Song, W.; Frost, H.; Vadseth, C.;
Narine, L.; Lenkiewicz, E.; Borchers, M. T.; Lusis, A. J.; Lee, J. J.; Lee, N. A.;
Abu-Soud, H. M.; Ischiropoulos, H.; Hazen, S. L., A tale of two controversies:
defining both the role of peroxidases in nitrotyrosine formation in vivo using
eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of
peroxidase-generated reactive nitrogen species. J Biol Chem 2002, 277, (20),
17415-27.

19.

Goldstein, S.; Czapski, G.; Lind, J.; Merenyi, G., Tyrosine nitration by
simultaneous generation of NO and O-(2) under physiological conditions. How
the radicals do the job. J Biol Chem 2000, 275, (5), 3031-6.

60

20.

Winterbourn, C. C.; Pichorner, H.; Kettle, A. J., Myeloperoxidase-dependent
generation of a tyrosine peroxide by neutrophils. Arch Biochem Biophys 1997,
338, (1), 15-21.

21.

Nair, U. J.; Nair, J.; Friesen, M. D.; Bartsch, H.; Ohshima, H., Ortho- and metatyrosine formation from phenylalanine in human saliva as a marker of hydroxyl
radical generation during betel quid chewing. Carcinogenesis 1995, 16, (5), 11958.

22.

Ye, Y. Z.; Strong, M.; Huang, Z. Q.; Beckman, J. S., Antibodies that recognize
nitrotyrosine. Methods Enzymol 1996, 269, 201-9.

23.

Kooy, N. W.; Lewis, S. J.; Royall, J. A.; Ye, Y. Z.; Kelly, D. R.; Beckman, J. S.,
Extensive tyrosine nitration in human myocardial inflammation: evidence for the
presence of peroxynitrite. Crit Care Med 1997, 25, (5), 812-9.

24.

Kato, Y.; Maruyama, W.; Naoi, M.; Hashizume, Y.; Osawa, T.,
Immunohistochemical detection of dityrosine in lipofuscin pigments in the aged
human brain. FEBS Lett 1998, 439, (3), 231-4.

25.

Kato, Y.; Wu, X.; Naito, M.; Nomura, H.; Kitamoto, N.; Osawa, T.,
Immunochemical detection of protein dityrosine in atherosclerotic lesion of apoE-deficient mice using a novel monoclonal antibody. Biochem Biophys Res
Commun 2000, 275, (1), 11-5.

26.

Chapman, A. L.; Senthilmohan, R.; Winterbourn, C. C.; Kettle, A. J., Comparison
of mono- and dichlorinated tyrosines with carbonyls for detection of
hypochlorous acid modified proteins. Arch Biochem Biophys 2000, 377, (1), 95100.

61

27.

Gujral, J. S.; Hinson, J. A.; Jaeschke, H., Chlorotyrosine protein adducts are
reliable biomarkers of neutrophil-induced cytotoxicity in vivo. Comp Hepatol
2004, 3 Suppl 1, S48.

28.

Berger, T.; Rubner, P.; Schautzer, F.; Egg, R.; Ulmer, H.; Mayringer, I.; Dilitz, E.;
Deisenhammer, F.; Reindl, M., Antimyelin antibodies as a predictor of clinically
definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003,
349, (2), 139-45.

29.

Beckmann, J. S.; Ye, Y. Z.; Anderson, P. G.; Chen, J.; Accavitti, M. A.; Tarpey,
M. M.; White, C. R., Extensive nitration of protein tyrosines in human
atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 1994,
375, (2), 81-8.

30.

Cromheeke, K. M.; Kockx, M. M.; De Meyer, G. R.; Bosmans, J. M.; Bult, H.;
Beelaerts, W. J.; Vrints, C. J.; Herman, A. G., Inducible nitric oxide synthase
colocalizes with signs of lipid oxidation/peroxidation in human atherosclerotic
plaques. Cardiovasc Res 1999, 43, (3), 744-54.

31.

Hill, K. E.; Zollinger, L. V.; Watt, H. E.; Carlson, N. G.; Rose, J. W., Inducible
nitric oxide synthase in chronic active multiple sclerosis plaques: distribution,
cellular expression and association with myelin damage. J Neuroimmunol 2004,
151, (1-2), 171-9.

32.

Good, P. F.; Hsu, A.; Werner, P.; Perl, D. P.; Olanow, C. W., Protein nitration in
Parkinson's disease. J Neuropathol Exp Neurol 1998, 57, (4), 338-42.

62

33.

Good, P. F.; Werner, P.; Hsu, A.; Olanow, C. W.; Perl, D. P., Evidence of
neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996, 149, (1), 218.

34.

Haddad, I. Y.; Pataki, G.; Hu, P.; Galliani, C.; Beckman, J. S.; Matalon, S.,
Quantitation of nitrotyrosine levels in lung sections of patients and animals with
acute lung injury. J Clin Invest 1994, 94, (6), 2407-13.

35.

Ceriello, A.; Mercuri, F.; Quagliaro, L.; Assaloni, R.; Motz, E.; Tonutti, L.;
Taboga, C., Detection of nitrotyrosine in the diabetic plasma: evidence of
oxidative stress. Diabetologia 2001, 44, (7), 834-8.

36.

ter Steege, J. C.; Koster-Kamphuis, L.; van Straaten, E. A.; Forget, P. P.; Buurman,
W. A., Nitrotyrosine in plasma of celiac disease patients as detected by a new
sandwich ELISA. Free Radic Biol Med 1998, 25, (8), 953-63.

37.

Onorato, J. M.; Thorpe, S. R.; Baynes, J. W., Immunohistochemical and ELISA
assays for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci
1998, 854, 277-90.

38.

Khan, J.; Brennand, D. M.; Bradley, N.; Gao, B.; Bruckdorfer, R.; Jacobs, M., 3Nitrotyrosine in the proteins of human plasma determined by an ELISA method.
Biochem J 1998, 332 (Pt 3), 807-8.

39.

Torreilles, J.; Romestand, B., In vitro production of peroxynitrite by haemocytes
from marine bivalves: C-ELISA determination of 3-nitrotyrosine level in plasma
proteins from Mytilus galloprovincialis and Crassostrea gigas. BMC Immunol
2001, 2, 1.

63

40.

Shigenaga, M. K.; Lee, H. H.; Blount, B. C.; Christen, S.; Shigeno, E. T.; Yip, H.;
Ames, B. N., Inflammation and NO(X)-induced nitration: assay for 3-nitrotyrosine
by HPLC with electrochemical detection. Proc Natl Acad Sci U S A 1997, 94, (7),
3211-6.

41.

Khan, J.; Brennand, D. M.; Bradley, N.; Gao, B.; Bruckdorfer, R.; Jacobs, M., 3Nitrotyrosine in the proteins of human plasma determined by an ELISA method.
Biochem J 1998, 330 (Pt 2), 795-801.

42.

Imam, S. Z.; el-Yazal, J.; Newport, G. D.; Itzhak, Y.; Cadet, J. L.; Slikker, W., Jr.;
Ali, S. F., Methamphetamine-induced dopaminergic neurotoxicity: role of
peroxynitrite and neuroprotective role of antioxidants and peroxynitrite
decomposition catalysts. Ann N Y Acad Sci 2001, 939, 366-80.

43.

Leeuwenburgh, C.; Rasmussen, J. E.; Hsu, F. F.; Mueller, D. M.; Pennathur, S.;
Heinecke, J. W., Mass spectrometric quantification of markers for protein
oxidation by tyrosyl radical, copper, and hydroxyl radical in low density
lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 1997, 272,
(6), 3520-6.

44.

Leeuwenburgh, C.; Wagner, P.; Holloszy, J. O.; Sohal, R. S.; Heinecke, J. W.,
Caloric restriction attenuates dityrosine cross-linking of cardiac and skeletal
muscle proteins in aging mice. Arch Biochem Biophys 1997, 346, (1), 74-80.

45.

Leeuwenburgh, C.; Hansen, P. A.; Holloszy, J. O.; Heinecke, J. W., Oxidized
amino acids in the urine of aging rats: potential markers for assessing oxidative
stress in vivo. Am J Physiol 1999, 276, (1 Pt 2), R128-35.

64

46.

Huggins, T. G.; Wells-Knecht, M. C.; Detorie, N. A.; Baynes, J. W.; Thorpe, S. R.,
Formation of o-tyrosine and dityrosine in proteins during radiolytic and metalcatalyzed oxidation. J Biol Chem 1993, 268, (17), 12341-7.

47.

Ischiropoulos, H.; al-Mehdi, A. B.; Fisher, A. B., Reactive species in ischemic rat
lung injury: contribution of peroxynitrite. Am J Physiol 1995, 269, (2 Pt 1), L15864.

48.

Salman-Tabcheh, S.; Guerin, M. C.; Torreilles, J., Nitration of tyrosyl-residues
from extra- and intracellular proteins in human whole blood. Free Radic Biol Med
1995, 19, (5), 695-8.

49.

Yi, D.; Ingelse, B. A.; Duncan, M. W.; Smythe, G. A., Quantification of 3nitrotyrosine in biological tissues and fluids: generating valid results by
eliminating artifactual formation. J Am Soc Mass Spectrom 2000, 11, (6), 578-86.

50.

Shigenaga, M. K., Quantitation of protein-bound 3-nitrotyrosine by highperformance liquid chromatography with electrochemical detection. Methods
Enzymol 1999, 301, 27-40.

51.

Morton, L. W.; Puddey, I. B.; Croft, K. D., Comparison of nitration and oxidation
of tyrosine in advanced human carotid plaque proteins. Biochem J 2003, 370, (Pt
1), 339-44.

52.

Hazen, S. L.; Crowley, J. R.; Mueller, D. M.; Heinecke, J. W., Mass spectrometric
quantification of 3-chlorotyrosine in human tissues with attomole sensitivity: a
sensitive and specific marker for myeloperoxidase-catalyzed chlorination at sites
of inflammation. Free Radic Biol Med 1997, 23, (6), 909-16.

65

53.

Davies, S. M.; Poljak, A.; Duncan, M. W.; Smythe, G. A.; Murphy, M. P.,
Measurements of protein carbonyls, ortho- and meta-tyrosine and oxidative
phosphorylation complex activity in mitochondria from young and old rats. Free
Radic Biol Med 2001, 31, (2), 181-90.

54.

Jacob, J. S.; Cistola, D. P.; Hsu, F. F.; Muzaffar, S.; Mueller, D. M.; Hazen, S. L.;
Heinecke, J. W., Human phagocytes employ the myeloperoxidase-hydrogen
peroxide system to synthesize dityrosine, trityrosine, pulcherosine, and
isodityrosine by a tyrosyl radical-dependent pathway. J Biol Chem 1996, 271, (33),
19950-6.

55.

Frost, M. T.; Halliwell, B.; Moore, K. P., Analysis of free and protein-bound
nitrotyrosine in human plasma by a gas chromatography/mass spectrometry
method that avoids nitration artifacts. Biochem J 2000, 345 Pt 3, 453-8.

56.

Pitt-Rivers, R., The oxidation of diiodotyrosine derivatives. Biochem J 1948, 43,
(2), 223-31.

57.

Hunt, S., Halogenated tyrosine derivatives in invertebrate scleroproteins: isolation
and identification. Methods Enzymol 1984, 107, 413-38.

58.

van Oss, C. J., On the mechanism of the cold ethanol precipitation method of
plasma protein fractionation. J Protein Chem 1989, 8, (5), 661-8.

59.

Abdelrahim, M.; Morris, E.; Carver, J.; Facchina, S.; White, A.; Verma, A., Liquid
chromatographic assay of dityrosine in human cerebrospinal fluid. J Chromatogr B
Biomed Sci Appl 1997, 696, (2), 175-82.

60.

MacPherson, J. C.; Comhair, S. A.; Erzurum, S. C.; Klein, D. F.; Lipscomb, M. F.;
Kavuru, M. S.; Samoszuk, M. K.; Hazen, S. L., Eosinophils are a major source of

66

nitric oxide-derived oxidants in severe asthma: characterization of pathways
available to eosinophils for generating reactive nitrogen species. J Immunol 2001,
166, (9), 5763-72.
61.

Pennathur, S.; Bergt, C.; Shao, B.; Byun, J.; Kassim, S. Y.; Singh, P.; Green, P. S.;
McDonald, T. O.; Brunzell, J.; Chait, A.; Oram, J. F.; O'Brien, K.; Geary, R. L.;
Heinecke, J. W., Human atherosclerotic intima and blood of patients with
established coronary artery disease contain high density lipoprotein damaged by
reactive nitrogen species. J Biol Chem 2004, 279, (41), 42977-83.

62.

Crowley, J. R.; Yarasheski, K.; Leeuwenburgh, C.; Turk, J.; Heinecke, J. W.,
Isotope dilution mass spectrometric quantification of 3-nitrotyrosine in proteins
and tissues is facilitated by reduction to 3-aminotyrosine. Anal Biochem 1998, 259,
(1), 127-35.

63.

Delatour, T.; Richoz, J.; Vouros, P.; Turesky, R. J., Simultaneous determination of
3-nitrotyrosine and tyrosine in plasma proteins of rats and assessment of artifactual
tyrosine nitration. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 779, (2),
189-99.

64.

Marvin, L. F.; Delatour, T.; Tavazzi, I.; Fay, L. B.; Cupp, C.; Guy, P. A.,
Quantification of o,o'-dityrosine, o-nitrotyrosine, and o-tyrosine in cat urine
samples by LC/ electrospray ionization-MS/MS using isotope dilution. Anal Chem
2003, 75, (2), 261-7.

65.

Knapp, D. R., Chemical derivatization for mass spectrometry. Methods Enzymol
1990, 193, 314-29.

67

66.

Kaur, H.; Halliwell, B., Evidence for nitric oxide-mediated oxidative damage in
chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid
patients. FEBS Lett 1994, 350, (1), 9-12.

67.

Fukuyama, N.; Takebayashi, Y.; Hida, M.; Ishida, H.; Ichimori, K.; Nakazawa, H.,
Clinical evidence of peroxynitrite formation in chronic renal failure patients with
septic shock. Free Radic Biol Med 1997, 22, (5), 771-4.

68.

Francescutti, D.; Baldwin, J.; Lee, L.; Mutus, B., Peroxynitrite modification of
glutathione reductase: modeling studies and kinetic evidence suggest the
modification of tyrosines at the glutathione disulfide binding site. Protein Eng
1996, 9, (2), 189-94.

69.

Kamisaki, Y.; Wada, K.; Nakamoto, K.; Kishimoto, Y.; Kitano, M.; Itoh, T.,
Sensitive determination of nitrotyrosine in human plasma by isocratic highperformance liquid chromatography. J Chromatogr B Biomed Appl 1996, 685, (2),
343-7.

70.

Malencik, D. A.; Zhao, Z. Z.; Anderson, S. R., Determination of dityrosine,
phosphotyrosine, phosphothreonine, and phosphoserine by high-performance
liquid chromatography. Anal Biochem 1990, 184, (2), 353-9.

71.

Ishida, N.; Hasegawa, T.; Mukai, K.; Watanabe, M.; Nishino, H., Determination of
nitrotyrosine by HPLC-ECD and its application. J Vet Med Sci 2002, 64, (5), 4014.

72.

Hensley, K.; Maidt, M. L.; Yu, Z.; Sang, H.; Markesbery, W. R.; Floyd, R. A.,
Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer
brain indicates region-specific accumulation. J Neurosci 1998, 18, (20), 8126-32.

68

73.

Crow, J. P., Measurement and significance of free and protein-bound 3nitrotyrosine, 3-chlorotyrosine, and free 3-nitro-4-hydroxyphenylacetic acid in
biologic samples: a high-performance liquid chromatography method using
electrochemical detection. Methods Enzymol 1999, 301, 151-60.

74.

Sawa, T.; Akaike, T.; Maeda, H., Tyrosine nitration by peroxynitrite formed from
nitric oxide and superoxide generated by xanthine oxidase. J Biol Chem 2000, 275,
(42), 32467-74.

75.

Kaur, H.; Fagerheim, I.; Grootveld, M.; Puppo, A.; Halliwell, B., Aromatic
hydroxylation of phenylalanine as an assay for hydroxyl radicals: application to
activated human neutrophils and to the heme protein leghemoglobin. Anal
Biochem 1988, 172, (2), 360-7.

76.

Edwards, D. J.; Sorisio, D.; Knopf, S.; Mujumdar, S., Assay for L-p-tyrosine in
plasma and brain by column liquid chromatography with electrochemical detection
using m-tyrosine as the internal standard. J Chromatogr 1986, 383, (1), 142-7.

77.

Hensley, K.; Maidt, M. L.; Pye, Q. N.; Stewart, C. A.; Wack, M.; Tabatabaie, T.;
Floyd, R. A., Quantitation of protein-bound 3-nitrotyrosine and 3,4dihydroxyphenylalanine by high-performance liquid chromatography with
electrochemical array detection. Anal Biochem 1997, 251, (2), 187-95.

78.

Korfmacher, W. A., Principles and applications of LC-MS in new drug discovery.
Drug Discov Today 2005, 10, (20), 1357-67.

79.

Gaut, J. P.; Byun, J.; Tran, H. D.; Heinecke, J. W., Artifact-free quantification of
free 3-chlorotyrosine, 3-bromotyrosine, and 3-nitrotyrosine in human plasma by
electron capture-negative chemical ionization gas chromatography mass

69

spectrometry and liquid chromatography-electrospray ionization tandem mass
spectrometry. Anal Biochem 2002, 300, (2), 252-9.
80.

Delatour, T.; Guy, P. A.; Stadler, R. H.; Turesky, R. J., 3-Nitrotyrosine butyl ester:
a novel derivative to assess tyrosine nitration in rat plasma by liquid
chromatography-tandem mass spectrometry detection. Anal Biochem 2002, 302,
(1), 10-8.

81.

Althaus, J. S.; Schmidt, K. R.; Fountain, S. T.; Tseng, M. T.; Carroll, R. T.;
Galatsis, P.; Hall, E. D., LC-MS/MS detection of peroxynitrite-derived 3nitrotyrosine in rat microvessels. Free Radic Biol Med 2000, 29, (11), 1085-95.

82.

Orhan, H.; Vermeulen, N. P.; Tump, C.; Zappey, H.; Meerman, J. H.,
Simultaneous determination of tyrosine, phenylalanine and deoxyguanosine
oxidation products by liquid chromatography-tandem mass spectrometry as noninvasive biomarkers for oxidative damage. J Chromatogr B Analyt Technol
Biomed Life Sci 2004, 799, (2), 245-54.

83.

Vlasova, II; Arnhold, J.; Osipov, A. N.; Panasenko, O. M., pH-Dependent
Regulation of Myeloperoxidase Activity. Biochemistry (Mosc) 2006, 71, (6), 66777.

84.

Duncan, M. W., A review of approaches to the analysis of 3-nitrotyrosine. Amino
Acids 2003, 25, (3-4), 351-61.

85.

Stafford, G., Jr., Ion trap mass spectrometry: a personal perspective. J Am Soc
Mass Spectrom 2002, 13, (6), 589-96.

86.

Badman, E. R.; Graham Cooks, R., Miniature mass analyzers. J Mass Spectrom
2000, 35, (6), 659-71.

70

87.

Noble, C. A.; Prather, K. A., Real-time single particle mass spectrometry: a
historical review of a quarter century of the chemical analysis of aerosols. Mass
Spectrom Rev 2000, 19, (4), 248-74.

88.

Tsikas, D.; Caidahl, K., Recent methodological advances in the mass
spectrometric analysis of free and protein-associated 3-nitrotyrosine in human
plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 814, (1), 1-9.

89.

Schwedhelm, E.; Tsikas, D.; Gutzki, F. M.; Frolich, J. C., Gas chromatographictandem mass spectrometric quantification of free 3-nitrotyrosine in human plasma
at the basal state. Anal Biochem 1999, 276, (2), 195-203.

90.

Herce-Pagliai, C.; Kotecha, S.; Shuker, D. E., Analytical methods for 3nitrotyrosine as a marker of exposure to reactive nitrogen species: a review. Nitric
Oxide 1998, 2, (5), 324-36.

91.

Yi, D.; Smythe, G. A.; Blount, B. C.; Duncan, M. W., Peroxynitrite-mediated
nitration of peptides: characterization of the products by electrospray and
combined gas chromatography-mass spectrometry. Arch Biochem Biophys 1997,
344, (2), 253-9.

92.

Fenaille, F.; Parisod, V.; Vuichoud, J.; Tabet, J. C.; Guy, P. A., Quantitative
determination of dityrosine in milk powders by liquid chromatography coupled to
tandem mass spectrometry using isotope dilution. J Chromatogr A 2004, 1052, (12), 77-84.

93.

Lorch, S. A.; Banks, B. A.; Christie, J.; Merrill, J. D.; Althaus, J.; Schmidt, K.;
Ballard, P. L.; Ischiropoulos, H.; Ballard, R. A., Plasma 3-nitrotyrosine and

71

outcome in neonates with severe bronchopulmonary dysplasia after inhaled nitric
oxide. Free Radic Biol Med 2003, 34, (9), 1146-52.
94.

Aldridge, R. E.; Chan, T.; van Dalen, C. J.; Senthilmohan, R.; Winn, M.; Venge,
P.; Town, G. I.; Kettle, A. J., Eosinophil peroxidase produces hypobromous acid
in the airways of stable asthmatics. Free Radic Biol Med 2002, 33, (6), 847-56.

95.

Buss, I. H.; Senthilmohan, R.; Darlow, B. A.; Mogridge, N.; Kettle, A. J.;
Winterbourn, C. C., 3-Chlorotyrosine as a marker of protein damage by
myeloperoxidase in tracheal aspirates from preterm infants: association with
adverse respiratory outcome. Pediatr Res 2003, 53, (3), 455-62.

96.

Bergt, C.; Pennathur, S.; Fu, X.; Byun, J.; O'Brien, K.; McDonald, T. O.; Singh, P.;
Anantharamaiah, G. M.; Chait, A.; Brunzell, J.; Geary, R. L.; Oram, J. F.;
Heinecke, J. W., The myeloperoxidase product hypochlorous acid oxidizes HDL
in the human artery wall and impairs ABCA1-dependent cholesterol transport.
Proc Natl Acad Sci U S A 2004, 101, (35), 13032-7.

97.

Atwood, C. S.; Perry, G.; Zeng, H.; Kato, Y.; Jones, W. D.; Ling, K. Q.; Huang,
X.; Moir, R. D.; Wang, D.; Sayre, L. M.; Smith, M. A.; Chen, S. G.; Bush, A. I.,
Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta.
Biochemistry 2004, 43, (2), 560-8.

72

CHAPTER III
PEROXIDASE PROMOTE PROTEIN BROMINATION IN
MULTIPLE MOUSE ACUTE IMFLAMMATION MODELS

3.1

Introduction

Asthma is an increasing health problem in the developed countries. In the United
States, over 17 million individuals, many of them are children, suffer form this chronic
pulmonary disease

1, 2

. The major symptoms of this airway obstruction include chronic

airway inflammation, recurrent recruitment and activation of leukocytes including
eosinophils and T cells into airway 3, 4. Eosinophil is one of the terminal effectors of the
innate immune system and specifically recruited to the inflammation sites. Over decades,
numerous studies support that eosinophil activation plays a vital role in airway
obstruction and lung dysfunction. Significantly increased eosinophils and their unique
granule proteins, including eosinophil peroxidase (EPO) and eosinophil cationic protein
(ECP), have been detected in peripheral blood, bronchoalveolar lavage (BAL), induced
sputum and bronchial mucosa specimens recovered from asthma patients
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5-7

.

The activated eosinophil participates host defense by generating reactive oxygen species,
including superoxide (O2•−) and hydrogen peroxide (H2O2), and simultaneously releasing
its unique granule proteins in response to the antigen stimulation 8, 9. EPO is account for
nearly 25% of the total protein mass of the secondary granule 10. Elevated EPO activity
was also observed in specimen recovered from patients with acute severe asthma 11. In
addition, EPO activities was associated with prompting mast cell degranulation,
activating platelets, and increasing the phagocytic capabilities of macrophages 12, 13.
In vitro studies indicate that EPO utilizes hydrogen peroxide to oxidize numerous

substrates including halide and pseudohalide thiocyanate

4, 14

. EPO selectively utilizes

physiological level of Br− (20-150 μM) over Cl− (100 mM) to generate hypobromous acid
(HOBr). Further, HOBr and its conjugate base (OBr−) react with amine and further
oxidize α- or β- amino acid. However, both oxidation products are labile and easily
decomposed to aldehyde 15, 16. N- dibromoamine (RNBr2) and N-bromoamine species are
easily reduced to non-informative products

17, 18

. Due to the evanescence character of

these reactive brominating species (RBS), it is impossible to use the RBS as a probe to
study the mechanism of EPO catalyzed oxidation in vivo. Direct evidence of EPO
induced protein modification in vivo has not been reported yet.
As an alternative way, stable oxidation products may serve as molecular
fingerprints to record peroxidase catalyzed oxidation in vivo.

Our previous study

indicated that EPO utilized H2O2 and physiological concentrations of Br− (20-150 μM) to
oxidize free or protein-bound L- tyrosine

19

. Two major products were detected by

ultraviolet-visible (UV) detector with distinct retention time on the reverse phase HPLC.
The two major products were further identified as 3-bromotyrosine (3-BrY) and 3,5-
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dibromotyrosine (3,5-diBrY) by electrospray ionization mass spectrometry and
multinuclear (1H and 15N) NMR spectroscopy. The stability of 3-BrY was demonstrated
by over 95% recovery even after treated by HCl (6N, 1% phenol) or methane sulfonic
acid (MSA, 4N, 1%phenol) at 110 °C for 24 hours (data not shown). The distinct
structure and relative stability of 3-BrY suggest that 3-BrY may be used as a specific
marker of peroxidase-catalyzed oxidation pathways in vivo. Recent studies indicate that
significantly elevated protein-bound 3-BrY is recovered in sputum in asthmatic patients
compared to that in controls. The levels of this bromination product highly positively
correlates with eosinophil peroxidase protein mass (r = 0.79, p< 0.0001)

20

. We also

found that protein-bound 3-BrY level increased 10-fold in bronchoalveolar lavage (BAL)
fluid recovered from asthmatic patients but only 2, 3-fold increased in that from healthy
controls after segmental allergen challenge21. Both in vitro and in vivo studies suggest
that 3-BrY can be used as a chemical probe to study eosinophil peroxidase catalyzed
protein bromination in vivo.
In current study, we monitored the generation of 3-BrY during allergen challenge
to evaluate the relative contribution of EPO in promoting protein bromination in vivo.
Multiple distinct inflammation models were used to generate robust eosinophil-rich
infiltration into airways or peritoneum in EPO knockout (EPO-/-) and wild-type (EPO+/+)
mice. The unique universally labeled tyrosine (13C9, 15N1 Tyr) was added prior to protein
hydrolysis to quantify natural abundance tyrosine and monitor the potential preparative
bromination generation during sample processing. Using this highly sensitive, selfquality control assay, the in vivo protein bromination is evaluated. Significantly elevated
3-BrY generation was observed in EPO+/+ mice in both models after allergen challenge.
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In addition, in helminth protein induced peritonitis model, significantly elevated 3-BrY
formation was observed after M.Corti. challenge (7-fold increases). Further, dramatic 3BrY generation (50-fold increases) was observed after zymosan triggered eosinophil
activation and degranulation in EPO+/+ mice.

In contrast, no detectable 3-BrY was

recovered in specimen from EPO-/- regardless the treatments. These results support the
EPO as the major pathway for generating protein-bound 3-BrY in vivo.
3.2

Experimental Procedures

Reagents

Reagents including H3PO4, NaH2PO4, and Na2HPO4 were purchased from Fisher
Chemical Co. Chelex 100 resin (200-400 mesh, sodium form) was purchased from
BioRad.

Methane sulfonic acid and bromide were from Fluka Chemical Co.

(Ronkonkoma, NY). L-[13C6] tyrosine, [13C915N1] tyrosine, and L-[2H4] tyrosine were
purchased from Cambridge Isotopes, Inc. (Andover, MA). All other reagents were
purchased from Sigma unless otherwise indicated. All gases were of the highest quality
available (Praxair, Cleveland, OH).
Animals

The animal studies described here were all performed using approved protocols
from the Animal Research Committees of the Cleveland Clinic Foundation and Mayo
Clinic Foundation. 129/SvJ age- and sex-matched EPO knockout (KO) and wild-type
(WT) mice were used for the allergen lung challenge and helminth antigen-induced
peritonitis studies.
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Aeroallergen Lung Challenge Model

EPO-KO and WT mice were sensitized by intraperitoneal injection with either
normal saline as control or 20 µg of ovalbumin (OVA, grade IV, Sigma) and 2.25 mg of
Imject® Alum (Pierce) on days 0 and 14. On days 24, 25, and 26, animals were
challenged with 20-min inhalations of a 1% OVA or normal saline aerosol. On day 28,
bronchoalveolar lavage (BAL) fluid was obtained by normal saline lavage. The recovered
BAL was centrifuged at 1000 rpm at 4 °C for 10 mins to remove cells. The supernatant
was frozen and stored under nitrogen at approximately –80 °C until analysis. Lung tissue
specimens of wild-type (EPO+/+) and EPO-/- mice were harvested 48 hours following the
last OVA aerosol challenge (i.e., the maxima of post challenge eosinophilia). Lung tissue
was immediately rinsed with an ice-cold anti-oxidant cocktail buffer (50 mM phosphate
buffer (pH=7.4), 100 µM diethylenetriaminepentaacetic acid (DTPA), 100 µM butylated
hydroxytoluene (BHT)) and stored under argon at approximately –80 °C until analysis.
Helminth Protein-induced Peritonitis Model

EPO-KO and WT mice were sensitized by subcutaneous injection with 250 µg of
whole protein extract from helminth Mesocestoides corti and 8 × 109 heat-killed pertussis
organisms (Michigan Department of Public Health, Lansing, MI).

Animals were

challenged with normal saline or 200 µg of M. corti. on day 21 by intraperitoneal
injection. Peritoneal cavity cells were harvested 72 hours later by lavage with 1x PBS
containing 100 µM BHT and 100 µM DTPA, 5% FCS and 20 U/mL heparin. For some
animals, the elicited peritoneal leukocytes (typically >2 × 106 cells, ~ 25% eosinophils)
were activated by intraperitoneal injection with zymosan (250 mg/kg of body weight).
Peritoneal lavage was performed 4 h after zymosan injection. Recovered leukocytes
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were washed three times with centrifugation/resuspension in 1x PBS before used.
Differential counts of cytospin preparations of these cells revealed that neutrophils
composed < 1% of all sample examined. The cell-free lavage fluid was overlaid with
argon and immediately stored at ~ –80 °C until analysis. Superoxide production was
measured as the superoxide dismutase-inhibitable reduction of cytochrome C

22

using

eosinophils isolated from EPO-KO and WT mice.
Immunocytochemical Detection of Eosinophils

Sections of lung tissue (4 µm) were assessed for the infiltration of eosinophils
using a rat mAb (14.7.4) specific for murine MBP-1

23

. Immunocytochemical staining

was performed with DAB-peroxidase detection reagents (Vector Laboratories,
Burlingame, CA) as described previously 24.
Cytochemical Detection of EPO

Cytospin preparations of peritoneal cavity cells harvested from MCAsensitized/challenged mice were prepared using a Cytospin3 (Shandon Scientific,
Cheshire, U.K.). The slides were subsequently fixed for 30 seconds at 4°C in a formalinacetone buffer (0.75 mM Na2HPO4, 7.5 mM KH2PO4 (pH 7.5), 45% (v/v) acetone, and
10% (w/v) formaldehyde), washed in tap water for several minutes, and stained (10 min
at room temperature) for EPO activity using a diaminobenzidine (DAB)-H2O2 phosphate
buffer (6 mM Na2HPO4, 286 mM KH2PO4 (pH 7.4), 2 mM (3',3')-DAB
tetrahydrochloride (Sigma, St. Louis, MO), 0.01% H2O2 (Sigma), and 8 mM NaCN
(Aldrich, Milwaukee, WI)) as described earlier 25. The concentration of CN- (8mM) was
used to selectively inhibit the activity of myeloperoxidase that may be present in the
sample. The staining reactions were terminated by washing under tap water, and the
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slides were counterstained with Harris hematoxylin (Sigma) before dehydration through
an ascending series of ethanol washes, incubation in xylene, and mounting with Permount
(Fisher Scientific, Pittsburgh, PA).
Endpoint Colorimetric Assessment of EPO Activity

The amount of EPO activity was determined by an endpoint colorimetric assay, as
described previously 26. To determine the amount of EPO activity within cells, peritoneal
cavity cells and/or leukocytes recovered from BAL fluid were washed in Kreb’s buffer
(118 mM NaCl, 25 mM NaHCO3, 11 mM glucose, 1 mM NaH2PO4•H2O, 5 mM KCl,
0.5 mM MgCl2•6H2O, and 2.5 mM CaCl2•6H2O (pH 7.4)) and counted on a
hemocytometer.

The number of eosinophils in a given leukocyte population was

determined by differential cell counts of cytospin preparations. Dilutions ranging from
102 to 104 eosinophils were seeded in 50-µl volumes in a 96-well microtiter plate, and
EPO activity was measured in each lysate through the addition 75 µl of
o-phenylenediamine-H2O2 buffer (50 mM Tris-HCl (pH 8), 0.1% Triton X-100, 4 mM
H2O2,

and

10

mM

of

the

EPO

(vs

myeloperoxidase)-specific

substrate

o-phenylenediamine). The reactions were allowed to proceed at room temperature for 30
minutes before adding 50 µl of stop buffer (2N H2SO4). Absorbance of each sample was
measured at 490 nm using a Vmax Kinetic Microplate Reader (Molecular Devices,
Sunnyvale, CA).

EPO activity present in BAL fluid was assessed by incubating

undiluted cell-free BAL fluid with o-phenylenediamine-H2O2 buffer at 37°C for 30
minutes 27. Colorimetric readings due to EPO activity were calculated as the difference
in absorbance measurement of each reaction with a duplicate reaction conducted in the
presence (30 mM) of the peroxidase inhibitor 3-amino-1,2,4-triazole. The fraction of
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EPO released from airway eosinophils was estimated by measuring the amount of EPO
activity in cell-free BAL fluid as a function of total EPO activity in the BAL (i.e., the
sum of EPO in the BAL fluid and EPO in airway eosinophils). EPO activity was
calculated from a standard curve established using 1 x 102–5 x 105 eosinophils purified as
a homogeneous population (99% pure) from an IL-5-transgenic mouse line

28

. The

reading at 490 nm of each sample (i.e., the BAL fluid and BAL cell pellet derived from
each mouse) was used to obtain the equivalent amount of EPO contained in a known
number of eosinophils as determined from this standing curve.
Preparation of Isotope Labeled Internal Standard

3-Bromo [13C6] tyrosine (13C6 3-BrY) was prepared by adding freshly made
NaOBr (final conc. of 1.5 mM) into a constantly stirring solution containing L-[13C6] ring
labeled tyrosine (final conc. 1 mM) and phosphate buffer (Final conc. 20 mM, pH= 7.4).
The resulting solution was incubated at 37°C for 2 hours before the addition of
trifluoroacetic acid (TFA) to terminate the reaction.

The acidified solution was

concentrated and isolated by a reverse-phase high performance liquid chromatography
(HPLC)

29

. Isotopically labeled tyrosine (13C6 Y) and 3-bromotyrosine (13C6 BrY) was

eluted with a linear gradient generated with solvent B (0.1% TFA in methanol, pH=2.0)
as follows: 0–5mins, 0% solvent B; 5–25mins, 0–100% solvent B; 25–28mins, 100 %
solvent B, 28–33 mins, 100%–0% solvent B. The isotopically labeled 3-BrY was then
dried in speed vacuum and kept in –20°C freezer until use.

Ring labeled 3-

Bromotyrosine was reconstituted with chelex-treated water. The identity and purity of
isotopically labeled 3-BrY was confirmed by LC/ESI/MS/MS.
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Tissue Collection and Preparation

On the day of analysis, tissues were thawed in sealed plastic vials under cool
running water.

All tissue processing steps were performed at approximately 4°C.

Samples were homogenized in PB buffer containing 100 µM BHT and 100 µM DTPA
using a Potter-Elvehjem tissue homogenizer with a PTFE pestle. Protein concentration of
lung tissue homogenate or extracellular lavage was determined using a Bradford-based
Bio-Rad protein assay with IgG as the protein standard. Protein (500 µg) was delipidated
and desalted using three sequential extractions with a single phase mixture of
H2O/methanol/H2O-saturated diethyl ether (1:3:8 v/v/v).

For each extraction, single

phase mixture was vortexed, stored at approximately –20 °C for 40 minutes. The protein
was precipitated by centrifuging at 4000 rpm for 20 mins at ~ 4°C. After discard
supernatant, protein pellet was dried under nitrogen steam. For each sample, known
amount

13

C ring-label 3-Bromotyrosine (13C6 BrY, 1.0 pmol) and universally labeled

tyrosine (13C9, 15N1 Y, 10 nmol), were added prior to protein hydrolysis.
Protein Hydrolysis and Derivatization

Preliminary studies demonstrated in acidic conditions, like methanesulfonic acid
(MSA, 4N, 1% phenol) or hydrochloric acid (HCl, 6N, 1% phenol) solution, free tyrosine
was stable at 110 °C for 24 hours. Artificial halogenation was eliminated by substituting
MSA (4N) for HCl (6N) and washing protein with single phase mixture prior to acidic
hydrolysis. Tubes were capped with gas-tight valves and alternately degassed and purged
with argon for 3 times. Protein pellet were hydrolyzed by 4N methanesulfonic acid
supplemented with 1% phenol at 110 °C for 24 hrs under argon atmosphere. The
potential debris generated during protein hydrolysis was removed by passing a mini
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solid-phase C18 column (Supelclean LC-C18 SPE mini-column, 3 ml; Supelco, Inc.,
Bellefone, PA). Briefly, protein hydrolysates (0.5 mL) were diluted with 1.5 mL Chelextreated water and load on pre-conditioned SPE columns. Following sequential washes
with 2 ml of water (0.1% TFA), 3-bromotyrosine and tyrosine were eluted with 2 ml of
30% methanol (0.1% TFA). The resulting amino acid solutions were then dried under
vacuum.
Before loading on a GC column, alkylation and acylation reactions were
accomplished to improve the gas chromatographic properties and enhance the sensitivity
of analytes. n-Propyl esters of tyrosine or 3- bromotyrosine were generated by adding a
mixture of 100 μl of n-propanol: concentrated HCl (3:1, v: v), and heating at 65°C for 75
minutes (Eq 1.). Reaction products were dried under vacuum and reconstituted with
100 μL of pentafluoropropionic anhydride: ethyl acetate (1:3, v: v) solution and
incubated at 65°C for 15 minutes to generate its n- propyl, per pentafluorylproprionyl
derivatives (Eq 2).

After evaporation under vacuum, derivatized amino acids were

reconstituted in 100 μL of ethyl acetate. An aliquot of resulting solution (1 μL) was
loaded on GC/MS for 3-BrY analysis.
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Eq 2.

Gas Chromatography-Mass Spectrometry

The amino acid derivatives were separated and analyzed on Trace GC-2000 gas
chromatography with online Voyager Mass Spectrometer (ThermoFinigann, San Jose,
CA). The separations were achieved on a 15m long, low bleeding RTX-200 MS column
(Restek, 0.25mm i.d., 0.25μm film thickness). Helium was used as carrier gas at a
constant flow rate of 1 mL/min. The initial oven temperature was maintained at 40°C for
1 minute, and then the temperature was increased to 150°C at 30°C/min, held at 150°C
for 0.5 minute, and then increased to 280°C at 15°C/minute. Tyrosine was analyzed by
split mode (split ratio, 50:1) and 3-Bromotyrosine was analyzed by splitless mode
respectively. Consistent septum purge was set on to keep septum clean. The injector,
transfer line and source temperature were set at 250°C, 250°C and 200°C respectively.
Derivatized tyrosine and 3-Bromotyrosine were detected and quantified by the
Voyager mass spectrometer via negative-ion chemical ionization (NICI) with selected ion
monitoring (SIM) mode. The emission current, electron energy and detector voltage was
set at 350 μA, 70Ev and 500 volts, respectively. n- propyl- per pentafluoroproprionyl
derivative of natural abundance 3-Bromotyrosine (12C9 BrY) was monitor at mass charge
ratio (m/z) of 445 (for 79Br), 447 (for 81Br), and their corresponding isotopically labeled
internal standard (13C6 BrY) at m/z ratio of 451 (for

79

Br), 453(for 81Br). To detect the

artificial generation during the hydrolysis and derivatization step, universally labeled
3-Bromotyrosine (13C9,
(for

81

15

N1BrY) was routinely monitored at m/z of 455 (for

79

Br), 457

Br). n- propyl- per pentafluoroproprionyl derivative of tyrosine (12C9 Y) and the

corresponding isotopically labeled internal standard (13C9 15 N1 Y) were monitored at m/z
ratio of 367 and 377, respectively. Both tyrosine and 3-bromotyrosine were base line
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resolved under current GC condition with at least 9-10 scans per chromatographic peak.
The 3-bromotyrosine content was normalized to the content of its precursor, tyrosine.
Statistical Analyses

Unless otherwise indicated, data were analyzed using an unpaired Student’s t tests.
The threshold for significance was set at p ≤0.05. The values for all measurements are
expressed as the mean ± S.D.
3.3

Results

OVA Challenge Induce eosinophilia in Both Wild Type and Knockout Mice

The localization of eosinophils within compartments of the lung after allergen
challenge was initially determined by an anti-mouse MBP rat mAb that was previously
demonstrated to be specific for eosinophils

24

. Figure 3.1 shows that although small

numbers of eosinophils are homeostatic resident cells in the lungs of both EPO+/+ and
EPO-/- mice, OVA challenge resulted in an influx of eosinophils into the
peribronchial/perivascular regions of EPO+/+ and EPO-/- mice.

The localization and

number of eosinophils (150–200 eosinophils per millimeter squared) in the lungs after
OVA challenge were indistinguishable between EPO+/+ and EPO-/- mice.
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Figure 3. 1

OVA-Sensitized/Challenged Induced Eosinophilia in EPO-/- and

EPO+/+ Mice

Trafficking of eosinophils to the perivascular and peribronchial regions of Wild
type (EPO+/+) and Knockout (EPO-/-) lungs was assessed by immunocytochemistry using
a rat mAb (14.7.4) specificially for mouse MBP-1. Saline control groups: A, EPO+/+ and
B, EPO-/-.

OVA–challenged groups: C, EPO+/+; and D EPO-/-.

Arrows indicate

eosinophils localized in the parenchyma of saline control EPO+/+ and EPO-/- mice. No
differences in the number or specific location of eosinophils recruited to the lung were
observed between similarly treated mice of either genotype. Scale bar = 100 µm.
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Eosinophils from Knockout Mice Are Peroxidase Deficient

The loss of EPO activity in knockout mice was demonstrated by cytochemical
staining of peritoneal cavity exudate cells recovered following sensitization/challenge of
mice with a whole-protein extract from the helminth M. corti. Figure 3.2 A shows that
eosinophils from EPO-/- mice were devoid of peroxidase activity (i.e., CN-–resistant
peroxidase activity (DAB staining) was demonstrated only in eosinophils from EPO+/+
and EPO+/- mice). The loss of eosinophil peroxidase activity in cells from EPO-/- mice
was further demonstrated using an endpoint colorimetric assay detecting EPO in lysate of
the peritoneal cavity exudates (Figure 3.2B).

The peroxidase activity of EPO+/-

eosinophils was roughly 50% of that found in EPO+/+ eosinophils, suggesting that EPO
levels in eosinophils are proportional to the number of wild-type EPO alleles present.
Eosinophils recovered from homozygous knockout mice derived from ES cell clone 6 or
57 were shown to be EPO activity deficient using both the peroxidase cytochemical
detection and the endpoint colorimetric assay. Thus, mice derived from either ES clone
were considered equivalent. Subsequent studies were performed on animals derived from
clone 57.
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Figure 3. 2

EPO Activity Is Absent in the Eosinophils of Knockout Mice.

A, EPO activity is detected only in eosinophils recovered from EPO+/+ and EPO+/-

mice in response to allergen challenge. B, EPO activity presented in eosinophils is in
proportion to the number of wild-type alleles. Assessments of peroxidase activity (490
nm), the number of eosinophils is plotted as a function of peroxidase activity in the
peritoneal cavity exudate. Eosinophils activity of EPO+/- contain half the peroxidase
activity as EPO+/+ cells. No peroxidase activity was detectable in cell lysate from EPO-/mice regardless of the input number of eosinophils. The points comprising each curve
represent the means of assays performed on exudated cells derived from four different
animals within each group. Error bars at each point represent ± SEM.
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GC/MS Analysis of 3-Bromotrysine

Negative-ion chemical ionization (NICI) mass spectrum of 1-propyl-per
pentafluoroproprionyl derivative of 3-Bromotyroisne was illustrated in figure 3.3.
Compared with low intensity of molecular ions (M•¯, 593 for 79Br and 595 for 81Br), the
base ion was observed at m/z 261 ([M− -CH2C5H4BrOOC2F5]), which was lack of
structure information. Other major fragment ions were observed with isotopic character
at m/z 573 ([M− -HF] for 79Br), m/z 575 ([M− -HF] for 81Br), m/z 445 ([M− -CF3CF2COH]
for 79Br) and m/z 447 ([M− -CF3CF2COH] for 81Br). The isotopic distribution of natural
abundance 3-BrY was confirmed by bromine-containing product ions (similar abundance
between

79

Br:

81

Br, 573: 575 and 445: 447). Product ions with corresponding isotopic

information 445, 447 were used to quantify natural abundance 3-Bromotyrosine because
their preserved the structure information and provided a better sensitivity compared to the
molecular ions (m/z 573 and 575).
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Figure 3. 3

Negative-ion chemical ionization mass spectrum of 3-bromotyrosine

1-propyl-per

pentafluoroproprionyl

derivative

of

3-Bromotyroisne

was

derivatized and analyzed by GC/MS in the NICI mode as described in experimental
procedures.

The structure of derivatized 3-BrY and its proposed fragmentation is

illustrated above. Molecular ions were observed at m/z ratio of 593 (for
(for 81Br).
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79

Br) and 595

Elevated 3-BrY Generation in EPO+/+ Mice after Allergen Challenge

The levels of protein-bound 3-BrY recovered from lung homogenate and
bronchoalveolar lavage (BAL) in an aeroallergen lung challenge model from wild-type
(WT, EPO+/+) and knockout (KO, EPO-/-) mice were quantified by isotope dilution
GC/MS assay to evaluate the potential involvement of EPO in the generation of
3-Bromotyrosine in vivo.

The topical chromatograms of 3-BrY in tissue specimen

recovered from an OVA–treat EPO+/+ mouse are presented in Figure 3.4.

For

quantitation purpose, each chromatographic peak contained a minimum 9-10 scans. The
natural abundance 3-BrY was identify by the corresponding isotope labeled internal
standard (13C6 BrY) and confirmed by the equal isotope abundance of bromine (79Br:81Br,
approximately 50:50). Native tyrosine and universally labeled tyrosine (13C9 15 N1 Y) are
identical in chemical structure expect that universally labeled tyrosine (13C9 15 N1 Y) has
ten extra atomic mass unit (10 Da). Therefore identical chemical character and same
chromatographic behavior should be observed in sample preparation and GC separation.
If trace amount of bromide was left in the system and caused bromination during sample
preparation, universally labeled 3-bromotyrosine (13C9
proportionally.

15

N1 BrY) will be generated

As demonstrated in Figure 3.4, there was no detectable universally

labeled 3-bromotyrosine (13C9

15

N1 BrY) indicating no detectable artifact generation

during sample process.
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Figure 3. 4

Detection of 3-bromotyrosine in Mouse Lung Tissue by GC/MS

Mouse lung tissue specimen from OVA–treated EPO+/+ mouse was prepared and
analyzed by GC/MS as described in experimental procedures. Native 3-BrY (m/z, 445
and 447) was identified by having the appropriate retention time compared to the
corresponding internal standards

13

C6 BrY (m/z, 451 and 453). No detectable ex vivo

bromination generation (13C9, 15N1 BrY, m/z, 455 and 457) was observed.
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The loss of peroxidase activity in knockout animals during allergen challenge was
functionally demonstrated by assessing an EPO-specific oxidation product, 3-BrY, in
whole-lung homogenates from EPO+/+ and EPO-/- mice using multiple allergen challenge
models. EPO+/+ (WT) and EPO-/- (KO) mice were pre-sensitized to antigen (Ovalbumin,
OVA) and then exposed to nebulized antigen. An eosinophil-rich leukocyte infiltration
was observed in lung and airway in both genotypes (Figure 3.1.). This similarity of
eosinophil infiltration was further confirmed by demonstrating comparable eosinophilia
recovered from bronchoalveolar lavage in WT and EPO-KO mice after OVA challenge
(BAL eosinophils, EPO+/+-, 0.97±0.29, EPO-/-, 1.0 ±0.30, p> 0.6). Lung specimens and
BAL lavage of EPO+/+ and EPO-/- mice were harvested 48 hr following the last OVA
aerosol challenge. The specimens were prepared following protein precipitation, acid
hydrolysis, solid phase extraction and derivatization. The level of 3-BrY in tissue or
BAL specimens from OVA–treated EPO+/+ and EPO-/- mice was normalized to the
content of its precursor, tyrosine, and presented in Figure 3.5. In EPO+/+ mice, the
contents of 3-BrY were significantly increased in whole-lung homogenates and BAL
after OVA challenge compared to saline-challenged controls (3-BrY/Y (µmol/mol), lung
tissue, OVA, 215, NS, 0, p< 0.05; BAL, OVA, 96, NS, 0, p< 0.05). No detectable 3-BrY
was observed in EPO-/- mice regardless treatments. The mouse Ovalbumin challenge
model did elicit a robust eosinophil-rich leukocyte infiltration into the lung and airway
(Figure. 3.1.). However, assessments of free EPO activity from BAL fluids from OVA–
treated WT mice only account about 9% of total activity. This limited degranulation may
contribute that only nominal protein bromination (3-BrY/Y, 96 µmol/mol) was observed
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in WT mice lavage after OVA challenge compared to that recovered in mild asthmatics
after segmental allergen challenge (3-BrY/Y, 1085 µmol/mol) 21, 31.
To further investigate EPO catalyzed protein bromination in vivo, an alternative
inflammation model, M. Corti/Zymosan peritonitis model, were applied and proteinbound 3-BrY was monitored.

EPO+/+ and EPO-/- mice were sensitized to induce

peritonitis and peritoneal lavage was harvested 72 hr after challenge.

Pilot study

indicated that sensitization/challenge helminth protein from M. Corti elicited a more
robust eosinophil-rich leukocyte infiltration into the peritoneum 72hr after the challenge
(topically > 2x106 cells, 25-30% eosinophils). In addition, yeast cell wall zymosan was
injected into the peritoneum to trigger extensive leukocyte activation and degranulation.
For some animals, as indicated, peritoneal lavage was recovered 72 hours after M. Corti
challenge and/or 4 hours after subsequent to intraperitoneal injection of zymosan (4hr).
Stable isotope dilution GC/NICI/MS quantification of protein-bound 3-BrY was
performed (Figure 3.6). Basal level 3-BrY levels were only observed in EPO+/+ mice
(BrY/Y, 10 ± 23 µmol/mol). 3-BrY levels were significantly increased in EPO+/+ mice
following M. Corti challenge compared with normal saline (7-fold increase, M. Corti, 71
± 58 µmol/mol; normal saline, 10 ± 23 µmol/mol, p <0.001). After M. Corti and zymosan
treatment, there was 50-fold increases over basal level 3-BrY generation (M.
Corti/zymosan, 499 ± 390µmol/mol; normal saline, 10 ± 23 µmol/mol, p <0.001). These

results confirm that elevated protein bromination consistent with helminth protein
induced peritoneal eosinophilia.

Zymosan induced leukocytes activation and

degranulation results in extensive EPO-catalyzed protein bromination in EPO+/+ mice.
However, 3- BrY was undetectable in the peritoneal lavage recovered from EPO-/- mice
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regardless the treatments. Parasite antigen induced extensive eosinophilia and zymosan
treatment stimulated eosinophil activation and degranulation failed to generate detectable
3-BrY in EPO -/- mice. This evidence strongly supports that loss of EPO activity links the
absence of protein bromination in vivo. Significantly elevated protein bromination in
EPO+/+ mice after allergen challenge supports the hypothesis that activated eosinophils
associate with protein bromination in vivo.

3-BrY serves as a specific molecular

fingerprint for EPO catalyzed bromination in vivo.
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Figure 3. 5

Elevated 3-BrY Generation in EPO+/+ Mice after Allergen Challenge

The lung/BAL specimens of EPO+/+ and EPO-/- mice were harvested 48 hr after
ovalbumin (OVA) or normal saline (NS) aerosol challenge. Isotope dilution GC/MS
analysis of 3-BrY/Y content: (A) in lung homogenates and (B) in extracelluar lavage
protein. The 3-BrY level was normalized to its precursor, tyrosine. Numbers in the
parentheses represent the sample size of each group. Data represent the mean ± SD.
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Figure 3. 6

Detection of 3-BrY in Lavage in Helminth-induced Peritonitis Model

EPO+/+ and EPO-/- mice were sensitized by subcutaneous injection with whole
protein extract from the helminth M. corti. Animals were challenged on day 21 by
intraperitoneal injection with either normal saline (NS) or M. corti to elicit an eosinophilrich peritoneal infiltrate. Where indicated, for some animals, peritoneal lavage was
recovered 72 hours after M. Corti challenge or 4 hours after subsequent to intraperitoneal
injection of zymosan.

The content of bromotyrosine in lavage supernatant was

subsequently measured by GC/MS. The level of 3-BrY was normalized to the protein
content of tyrosine, the precursor amino acid. Numbers in the parentheses represent the
sample size of each group. Values represent mean ± S.D.
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3.4

Discussion

Peroxidase catalyzed protein modification may be implicated in respiratory
disorders including asthma, rhinosinusitis

3, 4, 14, 32

. In vitro studies support reactive

intermediates generated by MPO/EPO react with variety of targets including protein,
lipid and genetic materials. Detection and quantitation protein-bound of stable oxidation
product has been used as a powerful tool to investigate peroxidase-catalyzed oxidative
pathways both in vitro and in vivo

14, 33-36

. In present studies, we showed significantly

elevated protein bromination in specimens recovered from EPO+/+ mice after allergen
challenge in multiple distinct inflammation models. Both OVA and M. Corti challenges
elicited a remarkable eosinophil-rich leukocytes infiltration into inflammation sites. Only
nominal levels of 3-BrY were observed in lung tissue specimens recovered from EPO+/+
mice. Zymosan, a potent trigger of leukocyte activation and degranulation, injected after
M. Corti challenges resulted a dramatic elevation in protein bromination in vivo. No

detectable protein-bound 3-BrY was observed in specimens recovered from EPO-/- mice
regardless the allergen challenge treatments. Our results support the EPO as the major
pathway for generating protein-bound 3-bromotyrosine in vivo.
To examine the potential role of EPO in 3-bromotyrosine generation in vivo, it
was fundamentally important to ascertain the genetic background of KO (EPO-/-) and the
loss of EPO activity. EPO knockout mouse was generated from 129/SvJ background by
replacing 3 target exons 37. Southern blot and RT-PCR were used to confirm the genetic
background of in EPO-/- mouse37. Electron Microscopy of eosinophils from EPO-/- mice
revealed the ultra structural changes of eosinophil secondary granules (detail in Ref

37

).

Cytochemical staining of eosinophils, which were recovered EPO-/- mice, demonstrated
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the loss of EPO activity (Figure. 3.2A). The loss of peroxidase activity in cells from
EPO-/- mice was further evaluated by using an endpoint colorimetric assay. No detectable
EPO activity in cell lysate from EPO-/- mice peritoneal cavity exudates (Figure. 3.2B).
The loss of EPO had no significant impact on the recruitment of leukocytes in
EPO-/- mice after allergen challenge.

48 hours after aerosol challenge, the similar

eosinophil infiltrations were observed in the lungs and airways recovered from EPO+/+
and EPO-/- mice. The localization and number of eosinophils (150–200 eosinophils per
millimeter squared) in the lungs after OVA challenge were indistinguishable between
EPO+/+ and EPO-/- mice (Figure. 3.1). This similarity was also confirmed by comparable
total cell counts in bronchoalveolar lavage recovered from EPO+/+ and EPO-/- mice
(eosinophils, EPO+/+ vs. EPO-/-, 0.97x104 vs. 1.0x104). Using helminth protein-induced
peritonitis model, a dramatic eosinophil-rich infiltration of leukocytes in peritoneum was
observed 72 hours after re-challenge regardless genotype. Comparable total cell count
(>2x 106 cells) and differentials (~25-30% eosinophils) were recovered in the peritoneal
lavage from EPO+/+ and EPO-/- mice.
The loss of EPO was associated with significantly elevated superoxide generation
in OVA challenge model. In vitro studies demonstrate that EPO-catalyzed free tyrosine
or protein-bound tyrosine bromination can be inhibited by eliminated the presence of
H2O2 or O2•- in the system

38

. To access EPO-catalyzed oxidation in vivo, the O2•-

generation of eosinophils recovered from EPO+/+ vs. EPO-/- mice was compared.
Superoxide production was consistently enhanced ~1.6 fold in eosinophils isolated from
EPO-/- mice compared to EPO+/+ mice of homogeneous genetic background (26 ± 4.8 vs.
41.5 ± 7.3 nmol/106 cells over one hr for WT vs. EPO-KO; p < 0.001).
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In the current study, the sample preparation procedures were optimized to prevent
artificial 3-BrY generation during sample preparation. In vitro studies indicate trace
amount of oxidized tyrosine can be generated at acidic condition in the present of
corresponding substrates 39, 40. Preliminary studies found that trace amount of 3-BrY was
detected by LC/MS after tyrosine incubated with HCl (6N, ACS certified) at elevated
temperature (data not shown). To prevent ex vivo 3-BrY generation, tissue specimens
were subjected to three sequential extractions with a single phase mixture of
H2O/methanol/H2O-saturated diethyl ether (1:3:8 v/v/v) to remove trace amount of
bromide. Traditional protein hydrolysis protocol is carried out in 6 N HCl for 24 hrs at
110 °C. Our preliminary studies found HCl (6N, ACS certified) might bring trace
amount of bromide into the system. To eliminate the artificial bromination generation
during protein hydrolysis, HCl (6N, 1% phenol) was substituted by methanesulfonic acid
(MSA, 4N, 1% phenol). The protein hydrolysis efficiency was examined by comparing
500 μg bovine serum albumin (BSA) in HCl (6N, 1% phenol) with that in MSA (4N, 1%
phenol) for 24 hrs at 110 °C (Table 3.1). The resulting free amino acids solution (10 μL)
was loaded on a C-18 ultrasphere column (Beckman, 5μm resin, 4.6mmx250mm) and
detected by UV detector at 280 nm (HPLC gradient listed in experimental procedures).
Similar hydrolysis efficiency was achieved by using MSA (4N, 1% phenol) for 24 hrs at
110 °C (Table 3.1). Constant boiling HCl (6N, ultra pure grade, 1 mL ampoule) was
used in derivatization to eliminate potential contamination.
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Table 3. 1

Protein Hydrolysis Efficiency

MSA (4N, 1% Phenol)

HCl (6N, 1% Phenol)

23565

25123

24766

23294

25194

20148

23443

20892

Mean

24242

22364

Std

871

2277

t test

0.201

Area

500 μg bovine serum albumin (BSA) was incubated with hydrochloric acid (6N, 1%
phenol) or methanesulfonic acid (MSA, 4N, 1% phenol) for 24 hrs at 110 °C. The
resulting free amino acids solution (10 μL) was loaded on a C-18 ultrasphere column and
detected by UV detector at 280 nm.
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It is necessary to monitor the ex vivo protein bromination due to the complexity of
biological matrices. Mass spectrometry is superior to other techniques because of its
better sensitivity and specificity. Immunohistochemical approaches have been widely
used to detect and localize post translational modification of protein within the tissue
both in vitro and in vivo 41-43. Immunochemical assay does not require extensive sample
preparation

43

. However, cross-reaction and semi-quantitative character dramatically

limit the utilization of this technique for quantitation purposes. The creditability of the
data is questionable due to lack of direct structural information of the analyte(s)

44, 45

.

High performance liquid chromatography (HPLC) and gas chromatography (GC) based
approaches are developed to detect oxidized tyrosine species using ultraviolet-visible
(UV), fluorescence, electrochemical detection (ECD) and mass spectrometer (MS)
detector

46 40, 47, 48

. Both UV and ECD detector are limited by providing adequate

sensitivity

49

. In addition, neither of them is able to identify any ex vivo oxidation

generation

50

. Mass spectrometer and unique isotope labeled internal standard addition

provided a powerful tool to detect the potential artifacts generation during sample
processing. Universally labeled tyrosine is added prior to protein hydrolysis to serve as a
chemical detector of preparative oxidation. Universally labeled tyrosine is structurally
identical to the natural abundance tyrosine except the difference in molecular weight.
During the sample preparation, if trace amount of anion ions are left in the acidic system,
natural abundance tyrosine (12C9,

14

N1 Tyr) and universally labeled tyrosine (13C9,

15

N1

Tyr) will be oxidized at the same reaction rate to generate distinct oxidation products
which can be only distinguished by the mass spectrometer
labeled tyrosine (13C9,

15

39, 51

. In deed, universally

N1 Tyr) is served as an internal quality controller for the
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potential ex vivo oxidized tyrosine generation to insure the final result only represent
oxidation stress in vivo.
Finally, using stable isotope dilution GC/MS and multiple inflammation models
in EPO+/+ and EPO-/- mice, we explore the mechanism of EPO-catalyzed bromination
pathway in response allergen challenge in vivo. Aerosolized saline challenge alone had
no effect on the homeostatic level of eosinophils in the airways from EPO-/- and EPO+/+
mice. After OVA challenge, significantly elevated eosinophils were recruited in both
EPO-/- and EPO+/+ mice. Eosinophil recruitments were indistinguishable in either
genotype. The loss of EPO in EPO-/- mice had no significant effect on eosinophil
recruitment in response to allergen challenge compared to EPO+/+ mice. Superoxide, one
of the reactive oxygen species (ROS), may serve as the fuel for the leukocyte implicated
oxidation. Even though the enhanced superoxide generation of eosinophils was found in
EPO-/- mice, protein bromination product was absent after OVA challenge.

One

explanation for the enhance superoxide generation by eosinophil from EPO-/- mice might
associate with the loss of EPO activity, which significantly decreased reactive oxygen
consumption by EPO-dependent oxidation in vivo.

In helminth protein induced

peritonitis model, the more eosinophil infiltration the higher bromination product was
observed in EPO+/+ mice (M. Corti, 71±58 µmol/mol vs. Normal saline, 3-BrY/Y 10±23
µmol/mol, p<0.01). In addition, zymosan stimulation triggered eosinophil activation and
degranulation results a 50-fold increase in 3-BrY content compared to the baseline
challenged by normal saline (M. Corti + zymosan , 499±39 µmol/mol vs. Normal saline,
3-BrY/Y 10±23 µmol/mol, p<0.001). On the other hand, no detectable 3-BrY was
observed in EPO-/- mice regardless treatments. This strongly supports that protein-bound
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3-Bromotyrosine serves a “molecular fingerprint” of EPO activation and induced
modification in vivo. Collectively, these results suggest that EPO is the major pathway
for the generating protein-bound 3-BrY in these allergen challenge models in EPO+/+ and
EPO-/- mice.
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CHAPTER IV
HIGH THROUGHPUT LC-MS/MS ASSAY FOR QUANTITATION
OF PROTEIN OXIDATION BY DISTINCT PATHWAYS IN
BIOLOGICAL MATRICES

4.1

Introduction

The failure of potential antioxidant strategies to influence the propensity to
develop a number of disease processes has raised considerable debate over the
significance of oxidative stress in disease pathogenesis. For example, α-tocopherol
supplementation in human clinical trials of cancer chemoprevention1-3 and cardiovascular
disease4-6 has for the most part failed to demonstrate clinical benefit. However, in
virtually all large-scale human clinical "anti-oxidant" studies there was no convincing
evidence that the interventions employed had any impact on oxidative events. This is
because concomitant systemic markers of oxidative stress were never performed, due in
large part to limitations in current methodology that permits performance of such
measures

in

a

practical

fashion

on

large
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numbers

of

clinical

specimens.

Of interest, where molecular markers of oxidant stress have been performed on
subjects supplemented with large doses of α-tocopherol, reductions in levels have not
always been observed7, whereas drugs with proven clinical benefit, such as statins for
cardiovascular risks, have shown potent systemic anti-oxidant effects as reflected by
multiple distinct oxidant stress markers8, 9.
Numerous lines of evidence support a mechanistic role for oxidative processes in
disease pathogenesis10-13. Increasingly, it is recognized that oxidative modification of a
number of proteins participates in the pathogenesis of aging and a number of disease
states including atherosclerosis, asthma and neurodegenerative disorders14-18. Protein
modification by reactive nitrogen species and halogenating oxidants (both brominating
and chlorinating species) lead to the generation of a number of stable products that can be
identified in a wide range of biological samples8, 19-27. As a result, the pathways that
promote protein modification have become potential targets for therapeutic intervention.
In addition, the detection of these products, which can act as molecular fingerprints of
disease processes (Figure 4.1), can potentially stratify patients according to their disease
risk, as well as potentially indicate which patients are most likely to benefit from
potential antioxidant promoting interventions8, 9, 23, 28.
The

leukocyte

derived

enzymes,

eosinophil

peroxidase

(EPO)

and

myeloperoxidase (MPO), have proven roles in the promotion of oxidative modification of
proteins in vivo. EPO, a granule protein secreted by activated eosinophils, preferentially
utilizes hydrogen peroxide and bromide as co-substrates to form reactive brominating
species including hypobromous acid (HOBr)29. MPO, secreted by activated neutrophils,
monocytes and certain tissue macrophages, can catalyze the formation of reactive
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chlorinating species such as hypochlorous acid (HOCl) and molecular chlorine (Cl2) by
utilizing hydrogen peroxide and chloride30. Nitric oxide (NO)-derived oxidants may also
be generated by EPO and MPO catalyzed pathways31-34, in addition to interactions with
peroxynitrite (ONOO¯), a potent oxidant formed by the reaction of nitric oxide and
superoxide35. Aromatic amino acid residues serve as prime targets for oxidative
modification. The side chain of tyrosine is preferentially modified by these reactive
species to form a number of oxidative products that are chemically stable and can be
detected in a wide variety of biological samples (Figure 4.1).
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Figure 4. 1

Chemical Structures of Molecular Fingerprints of Protein Oxidation

In Vivo

Hydroxyl radical can be generated by a redox-active metal ion (M2+) or a proteinbound redox-active metal ion [Pr (M2+)] and reacts with phenylalanine to form metatyrosine (m-Tyr) and ortho-tyrosine (o-Tyr). EPO and MPO generate reactive
brominating species (RBS) and reactive chlorinating species (RCS) which oxidize
tyrosine to form 3-bromotyrosine (BrTyr) and 3-chlorotyrosine (ClTyr). Tyrosyl radical
(·Tyr) cross reacts with tyrosine to form di-tyrosine (diTyr). Nitrogen dioxide (·NO2) can
be generated by enzymatic pathways working with peroxynitrite (ONOO¯) to oxidize
tyrosine and form 3-nitrotyrosine.
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Increasing evidence has emerged to highlight the role that oxidative protein
modification plays in the promotion of a number of diseases18, 36, 37. Reactive nitrogen
species have been implicated in the initiation of lipid peroxidation, protein nitration and
subsequent conversion of low density lipoprotein (LDL) into an atherogenic form38-41. It
has been demonstrated that systemic levels of protein-bound nitrotyrosine predicts a risk
of atherosclerotic disease in clinical studies and that levels decline following
administration of statin therapy, independent of the degree of LDL lowering8, 9. Further,
breast cancer samples with a high microvascular density are associated with elevated
tissue levels of nitrotyrosine42. Similarly, the content of apolipoprotein A-I chlorotyrosine
in subjects is strongly associated with cardiovascular risk23. Moreover, levels of
bromotyrosine in bronchoalveolar lavage (BAL) samples increase significantly following
allergen challenge in asthmatic subjects22. Bromotyrosine levels are significantly elevated
in BAL recovered from subjects with severe asthma21, and are elevated in both induced
sputum24 and urine43 of asthmatic subjects. It has also been reported that meta-tyrosine
and ortho-tyrosine, markers of protein oxidation by hydroxyl radical-like oxidants, can be
detected in vivo in a range of inflammatory settings9, 44, 45.
Because of the potential utility of protein oxidative modifications in determining
mechanisms of disease pathogenesis and oxidative processes in vivo, a number of
methods have been reported to quantify the levels of oxidized protein products in various
biological samples. The presence of oxidized protein products in tissue samples and
identification of their cellular origin have been demonstrated through several
immunochemical techniques using antibodies that are specific for protein oxidative
modifications

46-49

. However, many molecular markers of protein oxidation that are of
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interest do not yet have commercially available specific antibodies for their detection.
Moreover, antibody-based methods in general may be limited in their ability to accurately
quantify levels of individual specific oxidative products in varying sequence and protein
conformational contexts50. This is because antibodies typically display some degree of
cross-reactivity with other antigens and differing affinities for small haptens depending
upon the structural/sequence context in where the antigen resides. Finally, until multiple
specific antibodies and quantitative methods are developed, no current immunochemical
assays can simultaneously quantify multiple structurally distinct oxidized amino acids
and their precursors.
Alternative analytical approaches for oxidized amino acid quantification typically
involve in chromatographic separation of the components of protein hydrosylates by high
performance liquid chromatography (HPLC) or gas chromatography (GC), followed by
detection and quantification of oxidized aromatic amino acid species and their precursors
(tyrosine and phenylalanine) by ultraviolet detector (UV), electrochemical detection
detector (ECD), electron capture-negative chemical ionization mass spectrometry (ECNCI/MS) and electrospray ionization mass spectrometry (ESI/MS)25,

36, 51-56

. Mass

spectrometry is currently the only method that provides direct structural information of
the analyte as well as permits simultaneous monitoring for intra-preparative generation of
oxidative products during sample handling. The high sensitivity of mass spectrometry
allows for the detection of trace amounts of analytes in biological samples10, 25, 32, 57, 58.
Early mass spectrometry studies of oxidized amino acids employing isotopically labeled
precursor amino acids for the first time revealed the generation of artifactual intrapreparative

oxidized

amino

acids

such
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as

3-bromotyrosine

(BrTyr),

3,5-

dibrbromotyrosine

(Br2Tyr)22,

59

,

3-chlorotyrosine

(ClTyr)22,

59

,

3-nitrotyrosine

(NO2Tyr)59-61, and o,o'-dityrosine (diTyr)59. Use of isotopically labeled precursors has
subsequently been adopted by many others because of the power of the technique in finetuning sample preparation methods that exclude intra-preparative oxidation25, 32.
With accumulating evidence supporting a pivotal role for protein oxidation in a
wide range of disease processes, substantial interest has focused on the development of
analytical methods that can measure molecular markers of protein oxidation in vivo.
However, the labor- and time-intensive proposition of analyzing clinical specimens for
the presence of individual oxidation products in large scale human clinical studies
presents a daunting challenge. The development of a mass spectrometry-based approach
that permits simultaneous monitoring of an array of molecular markers of protein
oxidation while monitoring for the presence of artifactual intra-preparative oxidation
would appear to be a major advance in this field. Here we describe a highly sensitive and
specific assay for simultaneous quantification of 3-chlorotyrosine, 3,5-dichlorotyrosine,
3-bromotyrosine,

3,5-dibromotyrosine,

o-tyrosine,

m-tyrosine,

o,o'-dityrosine,

nitrotyrosine, and their respective precursor amino acids in biological tissues and fluids.
The method involves use of high performance liquid chromatography (HPLC) with online electrospray ionization tandem mass spectrometry (LC-ESI/MS/MS). The
incorporation of synthetic

13

C6-labled synthetic internal standards permits accurate

quantification of each natural abundance analyte. Inclusion of 13C9, 15N-labeled precursor
amino acids, tyrosine and phenylalanine, permits quantification of precursors and
monitoring for artifactual generation of oxidative products during sample processing
simultaneously. Use of column switching technique further enhances sample analysis
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throughput, resulting in a robust overall method with practical utility for both larger scale
clinical and animal model studies. The high sensitivity, specificity and detection of
multiple oxidized tyrosine species of this analytical method provides a unique
opportunity to both further delineate oxidative mechanisms in disease processes. It also
will enable exploration of the potential clinical utility of specific protein oxidative
modifications as diagnostic and prognostic indicators in human health and disease.
4.2

Experimental Procedures

Hydrochloric acid (optima), H3PO4, NaH2PO4, Na2HPO4 and all organic solvents
were from Fisher Chemical Co. (Pittsburgh, PA). Methanesulfonic acid and liquid
bromine were from Acros organics (New Jersey). Chelex 100 resin (200-400 mesh,
sodium from) was from BioRad (Hercules, CA). L-[13C6] tyrosine, L-[13C6]
phenylalanine and L-[13C9,

15

N1] universally labeled tyrosine and phenylalanine were

from Cambridge Isotopes (Andover, MA). All other reagents were purchased from Sigma
(St. Louis, MO) unless otherwise indicated. All gasses were of highest quality available
and were from Praxair (Cleveland, OH).
Human Studies

Normal levels of protein oxidation products in plasma were evaluated in samples
obtained from sequential healthy subjects who responded to local advertisements or were
participating in health care screenings following informed consent. Subjects who were at
least 25 years old with no history or clinical evidence of coronary artery disease were
eligible to enroll into study. These subjects had a mean (±SD) age of 52.0 (±11.9) years,
25.7% were current smokers, 27.1% had a history of hypertension and 10% had a history
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of diabetes. All participants provided written informed consents. The study protocol was
approved by the Institutional Review Board of the Cleveland Clinic Foundation.
Whole blood was collected into purple (EDTA) top vacutainer tubes and samples
were spun at 4 °C for 10 min at 2500 rpm. Plasma was removed and spiked with a 100X
stock solution of anti-oxidant cocktail comprised of diethylenetriaminepentaacetic acid
(DTPA) and butylated hydroxytoluene (BHT), resulting in a plasma final concentration
of 100 μM each. Specimens were snap frozen under Argon atmosphere in liquid nitrogen
and stored at approximately –80 °C until analyses.
Aeroallergen Lung Challenge Model

The animal studies were performed using approved protocols from the Animal
Research Committees of the Cleveland Clinic Foundation and University of Minnesota.
Three groups of adult age- and sex- matched Hartley guinea pigs were sensitized by
intraperitoneal injections of 500 μg of ovalbumin (OVA, grade IV, Sigma) with 50 mg
aluminum hydroxide adjuvant on days 0 and 14. One group of animals (Group 1, n= 5)
consumed a normal chow diet with drinking water throughout the study. On day 21 these
animals were challenged with aerosolized normal saline to serve as controls. Group 2
(n=6) received a normal chow diet with drinking water, while Group 3 (n= 6) received
drinking water supplemented with 0.2% sodium thiocyanate (NaSCN). On day 21,
animals in Groups 2 and 3 were both challenged by aerosolized normal saline
supplemented with 0.1% OVA solution. The challenge was performed for one minute on
five successive occasions, each separated by a minute of recovery. Two days later, the
animals were sacrificed. Lung tissue was harvested, immediately rinsed in ice-cold
normal saline and placed in 20 mM phosphate buffer saline (pH 7.4), supplemented with
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100 μM BHT and 100 μM DTPA, and overlaid with argon prior to storage at
approximately –80 °C until analyzed.
Tissue Homogenization

Samples were processed on the day of analysis. Tissue specimens were thawed
and immediately homogenized in ice-cold 20 mM PBS (pH = 7.4), containing 100 μM
DTPA and 100 μM BHT, using a Potter-Elvehjem Tissue Homogenizer with PTFE pestle.
The protein concentration of the tissue homogenate was determined using a Bradfordbased Biorad Protein Assay (Hercules, CA) with BSA as the standard.
Synthesis and Purification of Isotope Labeled Internal Standards

Isotope labeled precursors, [13C6] tyrosine and phenylalanine, were purchased
from Cambridge Isotopes. The purity and isotope composition of each isotope-labeled
amino acid was confirmed by mass spectrometry analyses to be > 99% pure before use in
syntheses. Isotope labeled 3-[13C6] bromotyrosine, 3-[13C6] chlorotyrosine, 3,5-[13C6] dibromotyrosine,

3,5-[13C6]

di-chlorotyrosine,

o,o’-[13C12]dityrosine

and

3-[13C6]

nitrotyrosine were synthesized as previously described20, 59, 62. m-[13C6] tyrosine and o[13C6] tyrosine were prepared from [13C6] phenylalanine63. Briefly, 3-Bromo [13C6]

tyrosine and 3,5-[13C6]di-bromotyrosine were prepared by adding fresh made NaOBr to
an equimolar concentration of L-[13C6] tyrosine solution in 20 mM PBS (pH 7.4) as
described previously59. The concentration of the NaOBr solution was determined on the
day of synthesis by UV spectrophotometer (ε331 = 315 M-1 CM-1, 0.1N sodium
hydroxide). The tyrosine/NaOBr solutions were incubated at 37°C for 2 hours, and
reactions stopped by the addition of large molar excess of methionine. Prior to HPLC
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purification, reaction mixtures were treated with trifluoroacetic acid (TFA) to adjust the
pH to 2. 3-[13C6] chlorotyrosine, 3,5-[13C6] di-bromotyrosine and 3-[13C6] nitrotyrosine
were synthesized from L-[13C6] tyrosine using an equimolar concentration HOCl, a 2.0
molar excess of HOCl and equimolar concentration of sodium peroxynitrite, respectively.
o,o’-[12C12]dityrosine and o,o’-[13C12]dityrosine were prepared by the oxidation reaction

of L-[12C6] tyrosine and L-[13C6] tyrosine, respectively, with hydrogen peroxide (H2O2),
catalyzed by horseradish peroxidase. m-[13C6] tyrosine and o-[13C6] tyrosine were
prepared from [13C6] phenylalanine.

H2O2 and CuSO4 (ratio, 100:1) were used to

generate the hydroxyl radical used in reactions to oxidize phenylalanine.
Each synthetic reaction mixture containing isotopically labeled amino acids were
first partially resolved and desalted using disposable mini solid-phase extraction (SPE)
columns. Samples were reconstituted with water containing 0.1% TFA and eluted with
30% methanol and dried under anhydrous nitrogen. The eluted material was individually
resuspended in chelex 100 (Bio-Rad, Hercules, CA) resin treated water and DTPA (final
concentration 100 μM) was added before loading material onto a reversed-phase
Ultrasphere ODS column (Beckman Instruments, Fullerton, CA, 10 mm x 250 mm, 5 μm
particle) for further purification. L-[13C6] ring labeled tyrosine and its oxidized products
were separated using reverse-phase HPLC using a diode array detector with dual
wavelength detection capability at 254 and 280 nm. Amino acids were eluted with a
linear gradient generated with solvent B (methanol). Universally labeled [13C9,

15

N1]

phenylalanine as commercially supplied was noted to typically require purification by
reverse-phase HPLC prior to use to eliminate trace amounts of contaminating universally
labeled ortho- and meta- tyrosine species.
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Before isolating isotopically labeled amino acids, the corresponding non-labeled
amino acids were used to optimize HPLC chromatographic condition, identify elution
times and develop calibration curve. After thorough rinsing of the HPLC system to avoid
isotope contamination from carry-over, individual internal standards were subsequently
purified by HPLC. The identity and purity of isotopically labeled standards were
individually confirmed by HPLC with on-line high-resolution mass spectrometry. The
isotope labeled internal standards were dried in a speed vacuum and stored at –20 °C.
General Procedures

Samples were maintained under argon to prevent artificial oxidation during
sample handling. In the event that samples could not be analyzed immediately, they were
purged with argon in gas-tight Cryovials (Corning Inc., Acton, MA), snap-frozen in
liquid nitrogen and stored at –80 °C. All buffers were treated with chelex-100 resin to
remove traces of residual transition metal ions. All glassware was treated with DTPA,
rinsed with chelex-100 resin treated water, and baked at 500 oC overnight prior to use.
The HPLC columns, filters, and solid phase extraction columns were also rinsed with
DTPA at neutral pH, and then cleaned with chelex-100 resin treated water. These
procedures were found necessary to preclude intrapreparative formation of o-tyrosine and
m-tyrosine during sample hydrolysis and analysis.
Desalting and Delipidation

Typically, samples are processed in batches of 50 or less. Samples (20 μL plasma
or 600 μg tissue homogenate) were diluted to 500 μL with H2O and spiked with DTPA to
achieve a final concentration of 100 μM. Ice-cold methanol (1.5 mL) and water saturated
ether (4 mL) were then added sequentially. The mixture was vortexed and maintained in
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a slush ice-bath for 20 minutes and then centrifuged at 2500 g for 20 min. The
supernatant was discarded and the protein pellet was briefly dried under a nitrogen stream
in an N-EVAP nitrogen evaporator (Organomation Associates Inc., Berlin, MA).
Desalting and delipidation was repeated one more time in the absence of DTPA
supplementation. The resulting protein pellet was dried under nitrogen prior to protein
hydrolysis.
Protein Hydrolysis

Known amounts of universally labeled [13C9,15N1] tyrosine (4 nmol) and
[13C9,15N1] phenylalanine (4 nmol) and 13C6-ring labeled internal standards (20 pmol each)
were added to the protein pellet, followed by the addition of 0.5 mL 4 M methanesulfonic
acid containing 1% phenol and 0.3% benzoic acid. Hydrolysis of the desalted protein
pellet was carried out under argon at 110 °C overnight (~18 hours).
Solid Phase Extraction

Protein hydrolysates were subjected to solid-phase extraction (SPE) to remove
acid and concentrate the analytes prior to LC/ESI/MS/MS analysis. Hydrolysates (0.5 mL)
were adjusted to 2 mL with Chelex-treated water and passed over a C18 solid phase
extraction column (Supelco Inc., Bellefonte, PA). The column was preconditioned with 6
mL methanol, rinsed with 6 mL 50 mM PB buffer containing 100 μM DTPA (pH 7.0),
followed by 6 mL Chelex-treated water and equilibrated with 0.1% TFA water.
Following sequential washes with 2 mL of 0.1% TFA water, the oxidized amino acids
and their precursors were eluted with 2 mL 30% methanol solution supplemented with
0.1% TFA. Samples were dried under vacuum (Speed Vac) and resuspended with 120
μL Chelex resin-treated water prior to analysis by mass spectrometry.
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Instrumentation

LC/ESI/MS/MS analysis of oxidized amino acids and their precursors was
performed using a triple quadruple mass spectrometer (ABI/Sciex 365, Applied
Biosystems, Foster city, CA) equipped with Ionics (Concord, Ontario, Canada) EP 10+,
EP XP, and HSID upgrades with electrospray ionization (ESI) needle connected to an
Aria LX4 series multiplexed HPLC system with Flux pumps (Cohesive Technologies,
Franklin, MA). The amino acid standards were separated over four matched Prodigy C18
columns (Phenomenex, 150 x 2.0 mm ID, 5 μm particle), each at a flow rate of 0.2
ml/min (Figure 4.2). Six oxidized tyrosine and phenylalanine species and the
corresponding precursors were separated within a 16 minute time-frame (2- 18 minutes).
The mobile phases used were 0.2% formic acid in water (solvent A) and 0.2% formic
acid in acetonitrile (solvent B). The elution conditions were as follows: the column was
first equilibrated with 100% A (0% B), held for 2 min at 100% A (0% B) immediately
after the injection, then a linear gradient was run from 100% A (0% B) to 82% A (18% B)
over 18 min, the linear gradient was then run from 82% A (18% B) to 20% A (80% B)
over the next 2 min. The gradient was held at 80% B for 4 min and immediately cycled
back to 100% A (0% B) for 12 minutes.
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Figure 4. 2

Topical Chromatograms of Oxidized Tyrosine Species Obtained with

Pure Standard Solutions by LC-MS/MS

Six oxidized tyrosine species and two precursors, the corresponding [13C6] labeled
internal standard and the universally labeled precursors (i.e. all carbons 13C, all nitrogen
15

N), were spiked into 20 μl HPLC grade water and processed as described in the

methods. Natural abundance oxidized tyrosine species and the precursors were identified
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by reverse phase HPLC coupled to tandem mass spectrometry in positive mode. The
retention times of Tyr, m-Tyr, diTyr, o-Tyr, Phe, ClTyr, NO2Tyr and BrTyr were 7.5, 9.8,
11.2, 11.7, 12.7, 14.2, 15.6 and 16.2 minutes respectively. Each natural abundance
oxidized tyrosine (arrow), the universally labeled artifact indicator (arrow) were
identified by the corresponding [13C6] labeled internal standard which posing exact
retention time and unique parent-daughter transition. As shown in the figure, no
universally labeled artifacts were detected in hydrolysated standard solution.
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The mass spectrometer was operated in positive ionization mode. The positively
charged molecules were selected by mass, and focused in the collision chamber
containing nitrogen gas. Each distinct parent-daughter ion transition was detected by an
on-line triple quadruple analyzer. The multiple-reaction monitoring (MRM) transitions,
the mass-charge ratio (m/z) for the molecular cation [MH]

+

precursor and the

corresponding product ions, used to detect the amino acid standards and their
corresponding isotopomers were listed in Table 4.1.
Instrument parameters were programmed for the ABI/Sciex API 365 with Ionics
EP 10+, EP XT collision cell upgrade and Hot Source-Induced Desolvation (HSID)
interface operated in the positive ionization mode. The ion spray needle was maintained
at 4000 volts. The turbo gas temperature was set at 500 °C. Ultra pure nitrogen was used
as the nebulizer gas (NEB, 15), curtain gas (CUR, 12) and collisionally activated
dissociation gas (CAD, 3). The Hot Source-Induced Desolvation (HSID) module was set
to 300oC. The peak width at the half-height (mass resolution) was set to one mass unit for
both Q1 and Q3. Other parameters were set as follows: declustering potential (DP), 13 V;
focusing potential (FP) 20; prefilter (ST) –18; focusing lens 1 (IQ1) –10.6; collision
energy (CE), 20; entrance potential (EP), 10; collision cell exit potential (CXP), 15. The
dwell time of each MRM pair was set at 0.1 sec with a 5 msec pause. The electronic
multiplier detector was set at 2500 volts with the repeller at –250 volts.
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Table 4. 1

Parent ÆDaughter Transition of Analytes
(Positive Ionization Mode)
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Statistical Analysis

Statistical analyses were performed using SPSS version 11.0. Data are presented
as mean ± SD. Comparisons between groups were performed using two-tailed unpaired
Student’s t tests with significance determined by p < 0.05. Spearmen-rank correlation
coefficients were used to assess associations between oxidized amino acid species.
4.3

Results

MS-MS Spectral Analysis of Tyrosine Species

The Q1 scan ESI/ MS analysis of all natural abundance oxidized tyrosine species
and their corresponding isotopomers was performed to confirm the purity and isotopic
pattern of the sample. Two approximately equally abundant ions with mass-charge ratios
at 260 and 262 were detected in the 3-Bromotyrosine spectrum. The mass-charge ratio
represents the protonated molecular ion [M+H] +. This isotopic pattern confirms the
presence of bromine (79Br:

81

Br; 49:51). Similarly, the presence of chlorine (35Cl:

37

Cl;

3:1) in 3-Chlorotyrosine was validated by the presence of two ions at m/z 216 and 218
with the relative intensity of 3 to 1 respectively (data not shown). Multiple reaction
monitoring (MRM) mode was used to increase specificity. The MRM transitions were
monitored for each natural abundance analyte, the corresponding isotopic internal
standard and universally labeled artifact. The loss of ammonia (NH3) from molecular ion
yields a product ion with m/z at [M +H-17]. The m/z ratios of parent-daughter transitions
of natural abundance analytes, isotope internal standards and artifact indicators are
summarized in Table 4.1. Naturally abundant dihalogenated tyrosine species (3, 5-diBromotryosine and 3, 5-di-Chlorotryosine) and their corresponding heavy isotope labeled
isotopomers were synthesized. The corresponding parent-daughter transition of each
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dihalogenated tyrosine is summarized in table 4.2. Using current HPLC condition, all of
the dihalogenated tyrosine species have distinct retention times and do not interfere with
the detection of mono-halogenated tyrosine and other oxidized tyrosine species.
Solid-Phase Extraction (SPE) Efficiency

The SPE extraction efficiencies of oxidized tyrosine species including
Bromotyrosine, Chlorotyrosine, dityrosine, meta-tyrosine, ortho-tyrosine and nitrotyrosine,
were evaluated by comparing peak areas of extracted analytes to those of neat standards.
The SPE recovery of each analyte was calculated from three independence experiments.
As shown in Table 4.3 A, the extraction efficiency of most of oxidized tyrosine was larger
than 85% except meta-tyrosine and ortho-tyrosine. The low recovery of ortho-tyrosine
and meta-tyrosine was compensated by the loss of corresponding isotope internal standard.
Thus, the low recovery of meta-tyrosine and ortho-tyrosine had no impact on the linearity
of the corresponding standard curve.
Linear Calibration Range and Limits of Detection

The seven-point standard curve was sequentially diluted from a primary cocktail
solution that contains natural abundance oxidized tyrosine species and their precursors,
tyrosine and phenylalaine.

All natural abundance oxidized tyrosine species were

identified and quantified by the corresponding [13C6] ring labeled isotopomer by
LC/MS/MS. The isotope internal standard cocktail which contained known amounts of L[13C9, 15N1] labeled tyrosine (4 nmol), phenylalanine (4 nmol) and of [13C6] ring labeled
oxidized tyrosine species (20 pmol) was added into solutions containing varying amounts
of natural abundance tyrosine, phenylalanine and oxidized tyrosine species. The analytes
and corresponding internal standards were processed and purified as unknown samples.

130

Peak areas of analyte and the corresponding internal standard were integrated by using the
Analyst Software (Version 1.4) provided by PE Sciex.

The calibration curve was

determined from peak area ratio vs. concentration ratio using linear regression. The
calibration curves for the amino acids are shown in figure 3. The correlation coefficient (r)
of each oxidized tyrosine species ranged from 0.995 to 0.999.
The limit of detection (LOD) of each oxidized tyrosine was achieved by injecting a
known amount of standard solution with a signal to noise ratio larger than 5. For each
analyte, the limit of detection (LOD) and limit of quantitation (LOQ) was listed in Table
4.3 A.
Reproducibility and Accuracy

To determine the accuracy and precision of this assay, known amount of natural
abundance tyrosine, phenylalanine and oxidized tyrosine species at three concentrations
(low, medium and high) in triplicates were spiked with isotope internal standard cocktail
and processed with calibration curves. Back-calculated concentrations of these samples
were used for determine of accuracy and precision. The accuracy of the method was
measured by relative error (RE%=100x Mean/Nominal) and precision was determined by
the coefficient of variation (CV%=100x standard deviation/ Mean). The precision values
of six oxidized tyrosine species were range from 0.0 to 8.48%. The accuracy values of all
analytes were range from -13.8 to 6.73% (detail in Table 4.3A). The ratio of oxidized
tyrosine and its corresponding precursors were also calculated. The precision values of
oxidized tyrosine/precursor were range from 0.986% to 10.7% and the accuracy values
from -4.79 to 10.2% (details in Table 4.3 B).
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Table 4. 2

Parent ÆDaughter Transition of Dihalogenated Tyrosines
(Positive Ionization Mode)
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Table 4. 3

Summary of Method Development

A
ClY

diY

m-Y

o-Y

NO2Y

LOD (pg)

2.46

8.62

14.4

3.62

1.81

1.13

LOQ (pg)

416

345

576

290

290

362

Recovery

92.5

85.7

91.2

35.5

34.0

86.1

Low

2.94

5.33

6.77

2.10

2.62

0.00

Med

3.28

5.74

8.48

1.97

1.15

6.62

High

1.68

5.12

2.98

3.02

5.90

1.95

Low

89.5

95.7

94.5

92.8

94.7

90.1

Med

100

107

107

101

102

98.5

High

97.7

104

91.5

99.7

101

96.8

BrY/Y

ClY/Y

diY/Y

m-Y/F

o-Y/F

NO2Y/Y

Low

2.90

3.23

4.95

4.81

4.43

4.92

Med

4.03

5.18

10.7

1.54

0.986

9.10

High

6.16

2.24

1.77

2.88

10.2

6.12

Low

97.1

104

102

108

110

97.9

Med

97.8

104

104

102

103

96.4

High

102

108

95.2

98.6

100

101

Accuracy
(RE%)

Precision
(CV%)

BrY

Accuracy
(RE%)

Precision
(CV%)

B

LOD: Limit of Detection, LOQ Limit of Quantitation The SPE recovery of each analyte
was calculated from three independence experiments.
CV (%) = (Standard deviation/mean) x 100
RE (%) = (Mean/Nominal Concentration) x 100
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Figure 4. 3

Calibration Curves of Oxidized Tyrosine Species.

The standard curve of each oxidized tyrosine was generated by incorporation of
the fixed amount of internal standard and varying levels of the corresponding analyte.
The resulting standard solutions were processed and analyzed by LC-MS/MS. Each
standard curve was plotted as peak area ratio versus mol ratio for each analyte. The linear
regression analysis of graphs revealed r values of 0.999, 0.999, 0.999, 0.999, 0.995, and
0.999 for m-Tyr, o-Tyr, Cl Tyr, diTyr, Br Tyr and NO2 Tyr respectively. Data points
represent the mean of triplicate determinations.
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Quantification of Protein-bound Oxidized Tyrosine Species in Human Serum

The normal ranges of each oxidized tyrosine species in human serum was
determined by analysis of blood collected from 140 healthy volunteers. The typical
chromatograms of a serum sample are depicted in figure 4.4. The natural abundance
tyrosine species were identified and quantified in relation to their corresponding ringlabeled isotope internal standard. As demonstrated in figure 4.4, there were no detectable
artifacts, which possess the anticipated m/z transitions for the corresponding universally
labeled oxidized amino acid. The amount of protein-bound oxidized tyrosine species was
normalized to its corresponding precursor, tyrosine and phenylalanine respectively. The
level of each species in healthy subjects is presented in figure 4.5. A strong correlation
was found between the m-Tyr/Phe and o-Tyr/Phe ratios (R= 0.57, p<0.001). Moderate
correlations were found between levels of chlorotyrosine with nitrotyrosine (R=0.366,
p<0.001), bromotyrosine (R= 0.207, p< 0.05), o-tyrosine (R=0.203, p<0.05) and mtyrosine (R=0.262, p<0.005) and between levels of bromotyrosine and nitrotyrosine (R=
0.219, p< 0.01). (Table 4.4)
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Figure 4. 4

LC- MS/MS Detection of Oxidized Tyrosine Species in Human Serum

Human serum (20 μL) was processed as described in the methods. Each natural
abundance oxidized tyrosine was detected and quantified by the corresponding stable
isotope labeled internal standard. The typical chromatograph of each analyte and the
corresponding characteristic MRM transitions was listed above. The retention time of
Tyr, m-Tyr, o-Tyr, diTyr, ClTyr, NO2Tyr and BrTyr were 6.1, 9.1, 11.4, 10.5, 13.2, 14.5
and 15.2 minutes respectively.
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Figure 4. 5

Serum Levels of Oxidized Tyrosine in Healthy Volunteers.

140 serum samples from healthy volunteers were analyzed by LC-MS/MS. The
result of each oxidized amino acid was normalized to the amount of its corresponding
precursor. In the box plots, the lower boundary indicates the 25th percentile, the line
within the box marks the median, and upper boundary of the box indicates the 75th
percentile. Error bars above and below the box indicate 95th and 5th percentile.
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Table 4. 4

Spearman Correlations Among Oxidized Tyrosine Species

In 140 healthy volunteer, the serum level of oxidation markers was studied to
further explore the underlining mechanism of oxidation in vivo. * p<0.05, ** p<0.01,
*** p<0.005 and **** p<0.001.
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Quantification of Oxidized Tyrosine Species in Guinea Pig Lung Tissue

As thiocyanate (SCN-) is a preferred substrate for EPO, it is possible that
increased systemic level of SCN- following dietary supplementation may result in
preferential oxidation of SCN- in comparison with halide species including Br- and Cl-.
To test this hypothesis, the effect of dietary SCN- supplementation on an aeroallergen
challenge model of asthma in age- and sex- matched Hartley guinea pigs was determined.
In animals fed normal chow, lung levels of 3-BrTyr increased following challenge with
OVA, in comparison with normal saline. This further supports the notion that aerosol
exposure with OVA is associated with enhanced bromination in lung tissue. However, the
allergen induced increment of bromination was completely abrogated by dietary
supplementation with SCN- prior to OVA challenge. This result suggests that dietary
supplementation with SCN- enriched food may afford relief from oxidative injury of lung
and airway proteins during the asthmatic response. (Figure 4.6)
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Comparison of the Levels of Oxidized Tyrosine Species in OVA

Challenged Model

Hartley guinea pigs were fed a normal diet (SCN-, n=11) or thiocyanate enriched diet
(SCN-, n=6). The animals on normal diet were sensitized with ovalbumin (SCN-, OVA+,
n=6) or normal saline (SCN-, OVA-, n=5) on days 0 and 14, then challenged later on day
21 with aerosolized either OVA or normal saline. OVA challenge were also performed on
the animal with thiocyanate enriched diet (SCN-, OVA+, n=6). 48 hours after the
challenge, lungs were harvested and preserved. The oxidized tyrosine species and their
precursors were quantified by LC/MS/MS. The result of each oxidized amino acid was
normalized to the amount of the corresponding precursor. Values represent mean ± SD.
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4.4

Discussion

As evidence accumulates supporting a pivotal role for oxidized tyrosine species in
the pathogenesis of a wide range of disease processes, it has become important to develop
accurate analytical methods to quantify the levels of these products in vivo. The
generation of oxidized tyrosine species has been implicated in the development of
atherosclerotic plaque, asthma and breast cancer. In addition, it has been demonstrated
that protein-bound levels of nitrotyrosine decline in response to statin therapy. These
molecular fingerprints have the potential to be developed as a marker of disease risk and
activity. In order to be a useful clinical biomarker it is necessary to develop accurate
analytical methods that can rapidly and reproducibly quantify levels in a range of
biological matrices. The use of the bench top triple quadrupole LC/MS/MS method
described in this report fulfills these criteria.
The method can be subject to modification depending on the clinical scenario.
Biological matrices containing high levels of endogenous nitrite/nitrate, such as salivary
fluid and endobronchial aspirates, often require additional desalting steps. In addition,
different methods for protein hydrolysis can be used, depending on the oxidized species of
interest. As the described method aims to measure levels of multiple oxidized species
simultaneously, methanesulfonic acid is typically used. In contrast, when it is unnecessary
to measure chlorotyrosine levels, acid hydrolysis is often performed using hydrochloric
acid. Similarly, the total monitored precursor-product transitions can be adjusted to fulfill
the requirement of sensitivity and specificity. When using different biological matrices,
protein concentration and extraction procedure should be re-evaluated to eliminate ex vivo
artifacts generation prior to proceeding with sample assays.
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The CVs of QC samples (oxidized tyrosine/precursor, three concentrations in
triplicates) were ranged from 0.986 to 10.7%. To determine the coefficient of variations
of real samples, five replicates of two human serum samples were also processed and the
CV of protein-bound of bromotyrosine, chlorotyrosine, dityrosine, meta-tyrosine, orthotyrosine and nitrotyrosine were range from 11 to 22%, 25 to 30%, 22 to 33%, 13 to 18%,
14 to 18%, and 29 to 30%. The high variations of protein-bound of oxidized tyrosine
species may reflect the complex of oxidized tyrosine residue in sample and the variation
of protein recovery during desalting and delipidation step.
This analytical method can be particularly useful because it can be applied to a
large number of samples simultaneously. Furthermore, it demonstrates a high sensitivity
and specificity for the detection and quantification of a number of oxidized species at the
same time. The low limit of detection of standard samples is consistent with previous
reports of assays using triple quadrupole systems. Incorporation of heavy isotope labeled
internal standards that assist in the detection of artifactual generation of oxidized products
ex vivo during sample preparation is a key component of this assay. Using these standards,

we have found that the degree of artifactual oxidation is minimal. In the rare event that the
level of artifactual species exceeded 5% of the total level detected, we repeated the sample
preparative step with a more exhaustive desalting step. In certain circumstances it is
necessary to modify the sample preparation to eliminate intra-preparative artifacts
generation. In patients receiving nitrate therapy in the setting of acute coronary syndromes,
an extra desalting step is often required to remove the excess nitrate when assaying
nitrotyrosine levels.
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The ability to determine levels of multiple oxidized markers in biological samples
expands our understanding of the role of particular oxidative pathways in the pathogenesis
of a range of disease processes. The correlations between individual oxidized species,
demonstrated in the serum of healthy volunteers, provides insight into the pathways that
generate these species in vivo. The strong correlation between levels of m-tyrosine and otyrosine highlights the role of phenylalanine hydroxylation. Similarly, correlations
between the level of 3-ChloroTyrosine with both 3-NitroTyrosine and 3-BromoTyrosine,
and between levels of 3-BromoTyrosine and 3-NitroTyrosine, are consistent with in vivo
activity of myeloperoxidase and eosinophil peroxidase respectively. These relationships
provide chemical evidence that pathways induced by leukocyte activation contribute to the
generation of oxidative stress in vivo. The current study adds further support for the notion
that bromination, catalyzed by the leukocyte derived enzyme eosinophil peroxidase, is
enhanced in an animal model of aeroallergen challenged asthma. In addition, elevated
peripheral SCN- from dietary supplement partially inhibits EPO catalyzed protein
bromination in vivo. Increase systemic level of SCN- may become a potential strategy for
therapeutic intervention of EPO induced oxidative modification.
In summary, the current report describes the development of an analytical method
using a bench top triple quadrupole LC/MS/MS system that reliably detects and
quantifies oxidized tyrosine species and their precursors in a wide range of biological
matrices. This method avoids the need for chemical derivatization of samples and
minimizes the possibility that artifactual generation of oxidation products may interfere
with the detection of native levels. The evolution of bench top mass spectrometric
systems allows for the ability to analyze multiple samples simultaneously. As a result, the
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detection of levels of oxidized products in biological samples has provided further
insights into the specific oxidative pathways that promote the pathogenesis of a wide
variety of disease processes.
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CHAPTER V
NASAL MUCOSA IS A SANCTUARY SITE FOR ENHANCE
OXIDATIVE STRESS AS REVEALED BY MOLECULAR
FOOTPRINTS OF MULTIPLE OXIDATIVE PATHWAYS

5.1

Introduction

The mucosal lining of the nose and paranasal sinuse serves as an important barrier
between the host and the external environment. This barrier function occurs in two
principal ways. Firstly, the mucosa provides a physical covering that blocks the entry by
potentially pathogenic micro-organisms and non-living substances.

Secondly, the

immune system performs its surveillance function against non-self antigens within the
mucosa and along its surface. The immune system targets specific antigens through the
processes of adaptive immunity, which is mediated by both T- and B-cells. Innate
immunity provides nonspecific protection against nonself antigens. Mechanisms for
innate immunity include phagocytosis (by neutrophils, monocytes and macrophages),

154

the complement cascade and peroxidases (secreted by neutrophils, monocytes,
eosinophils, etc.). Because innate immunity is intrinsically nonspecific, its action may
inadvertently damage host tissues.

Derangements of immune system function in

sinonasal mucosa lead to a wide variety of chronic inflammatory conditions, including
allergic rhinitis (AR) and rhinosinusitis (RS, previously termed sinusitis).
Approximately 31 million Americans report suffering from RS 1. The hallmark of
this condition is a chronic inflammatory infiltration 2. The etiology of RS is unknown
bacteria, fungus and immunological dysfunction. Outcome studies have confirmed that
RS has a large adverse impact on patient quality of life measures including reductions of
patient sense of physical, functional and emotional well-being 3 4.
Once activated, eosinophils and neutrophils are recruited to the sites of
inflammation and release unique leukocytes peroxidases and cytotoxic granule proteins,
including major basic protein (MBP) 5.

The leukocytes peroxidases, eosinophil

peroxidase (EPO) and myeloperoxidase (MPO), are some of the most abundant proteins
in these cells

6 7

. In the past several years, studies suggest that EPO and MPO utilize

H2O2 with halides or pseudohalides as co-substrates to generate reactive hypohalous acid
(HOX): H2O2 + X- + H+ Æ HOX + H2O (X= Br-8, Cl- 9, I- 10 and SCN- 11 respectively) to
fight invading pathogens 12. Although peroxynitrite (ONOO-), the reactive species formed
by nitric oxide radical (NO˙) and superoxide (O2˙-)13, is believed the major reactive
nitrogen species (RNS), recent studies support EPO and MPO may also participate to
generation of RNS14-16. Using free or protein-bound tyrosyl residues as substrate,
EPO/MPO also participates the formation of tyrosyl radical

17

. Further, redox-active

metal ions interact with H2O2 to generate hydroxyl radical (HO˙)18(Fig. 5.1.).
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Figure 5. 1

Reactive Intermediates Generated by Enzymatic Ppathways and Free

Metal Ions React with Tyrosine and Phenylalanine

EPO and MPO utilize hydrogen peroxide and various substrates, including
bromide, chloride, tyrosine and nitrite (NO2-) to generate an array of reactive
intermediates: hypobromous acid and hypobromite ion (HOBr/OBr-), hypochlorous acid
and hypochlorite ion (HOCl/OCl-), tyrosyl radical and nitrogen dioxide (NO2˙). Another
reactive nitrogen species, peroxynitrite (ONOO-), is generated by the interaction of nitric
oxide radical with superoxide. Redox-active metal ion (free or protein-bound) reacts
with hydrogen peroxide to generate hydroxyl radical (˙OH). These reactive intermediates
react with tyrosine or phenylalanine to generate distinct molecular fingerprints of 3BrTyr, 3- 3-ClTyr, di Tyr, 3-NO2Ty, m-Tyr and o-Tyr, respectively.
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These reactive oxidants provide host defense mechanisms against pathogenic
organisms through oxidative modifcation. Obviously, the reactions of RBS, RCS, RNS,
tyrosyl radical, hydroxyl radical and peroxynitrite are all non-specific, and inevitably host
tissues can be modified through these oxidations. Host tissue injury may be assessed
through quantifying the amounts of stable end-products, which serve as a molecular
footprint of the oxidative modification. Previous studies have demonstrated that RBS,
RCS, RNS and tyrosyl radicals oxidize protein-bound tyrosine residues to produce 3bromotyrosine (3-BrTyr)19, 20, 3-chlorotyrosine (3-ClTyr) 21, 22, 3-nitrotyrosine (3-NO2Tyr)
15, 23

and o, o’-di-tyrosine (di Tyr)

24

, respectively. Similarly, hydroxyl radicals convert

protein-bound phenylalanine residues to meta-tyrosine (m-Tyr) and ortho-tyrosine (oTyr). 25, 26
The current study seeks to demonstrate patterns of oxidative metabolism in
sinonasal mucosa under normal conditions and in the presence of chronic inflammation.
This approach highlights the presence of oxidants produced by both EPO and MPO under
normal, healthy conditions. In addition, this method may serve as a powerful tool for the
study of mechanisms of RS pathogenesis.
5.2

Experimental Procedures

Subjects

RS patients (n=42) were recruited from the clinical practices of the Section of
Nasal and Sinus Disorders in Cleveland Clinic Foundation Head & Neck Institute. A
symptom-based history of chronic RS, as defined by the criteria established by the Sinus
and Allergy Health Partnership27, was present in all RS patients. All RS patients reported
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symptoms of rhinorrhea and nasal obstruction, and the clinical diagnosis was confirmed
through nasal endoscopy and CT scan. Atopy was assessed through a RAST inhalent
panel that measured specific IgE for a variety regionally relevant allergens (specific IgE
to Timothy grass, June grass, Bermuda grass, short ragweed, English plantain, Lamb’s
quarters, box elder tree, oak tree, Elm tree, cat dander, dog dander, Penicillium notatum,
Cladosporium herbarum, Aspergillus fumigatus, Alternaria tenuis, house dust and
Dermatophagoides farinae analyzed by ImmunoCap, Pharmacia & Upjohn, Kalamazoo,
MI). RS patients with a positive RAST panel (defined as detectable Class I or greater
reaction for one or more antigens) were grouped into the allergic rhinosinusitis (ARS)
group, while the remaining patients with a negative RAST panel were grouped into the
nonallergic rhinosinusitis (NARS) group.
A total of 16 volunteers were recruited by local advertisements following
informed consent. Only ten subjects who were at least 25 years old with normal Ig E and
RAST panel were eligible to enroll into study.
The Cleveland Clinic Foundation Institutional Review Board approved the
protocol.
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Table 5. 1

Population Characteriistics

Controls

Rhinosinusitis (RS)

(n=10)

(n=42)

Age (Mean ± SD)

28.1 ± 7.7

51.4 ± 11.3**

Male gender (%)

60

60

IgE (Unit per ml)

21.7 ± 20.2

263.1 ± 522.5*

Eosinophil differential (%)

2.8 ± 1.5

5.1 ± 3.4*

Abnormal RAST panel (%)

0

40**

Asthma (%)

0

50**

Steroid (%)

0

70**

Comparison RS vs. control: * = p< 0.01, ** = p< 0.01;
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Sample Collection and Storage

Sinonasal mucosa was obtained from RS patients under endoscopic visualization,
and middle turbinate biopsies were performed in control subjects under endoscopic
visualization. Approximate tissue size was 3 mm x 3 mm x 3 mm. Tissue samples were
immediately placed in the ice-cold antioxidant phosphate buffer (100 µM DTPA, 100 µM
BHT, PB, 20 mM, pH 7.4) and overlaid with argon and saved in approximately –80 °C
until analysis.
At the time of biopsy, sera samples were collected from all subjects.

Sera

samples were then spiked with anti-oxidant cocktail (100 µM DTPA, 100 µM BHT),
covered by argon layer and stored frozen at approximately –80 °C freezer.
Preparation of Tissue

All samples were processed on the date of analysis. Tissue specimens were
thawed and immediately homogenized in ice-cold PBS buffer (100 μM DTPA, 100 μM
BHT, PB= 20mM, pH = 7.4) using a Potter-Elvehjem Tissue Homogenizer with a PTFE
pestle.

A Bradford-based Biorad (Hercules, CA) Protein Assay with human serum

albumIn (HSA) as the standard was used for determination of protein concentration.
Materials

All solvents were purchased from Fisher Chemical Co. (Pittsburgh, PA,) and were
the highest or HPLC grade. All other reagents were purchased from Sigma (St. Louis,
MO,) unless otherwise indicated. All gasses were of highest quality available and were
from Praxair (Cleveland, OH). Isotopically labeled amino acids were from Cambridge
Isotopes (Andover, MA).
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Preparation and Purification of Isotope-labeled Internal Standard

Isotopically labeled 3-[13C6] bromotyrosine, 3- [13C6] chlorotyrosine, and 3-[13C6]
nitrotyrosine and o, o’-di Tyrosine were synthesized as previously described

17, 19, 28, 29

.

m-[13C6] tyrosine and o-[13C6] tyrosine were synthesized using [13C6] phenylalanine,
copper and H2O2

30

. Each isotopically labeled compound solution was purified by

reversed-phase HPLC and collected at the exactly same retention time of the
corresponding natural abundance oxidized tyrosine. The identity and purifity of isotop
internal standard was confirmed by LC/MS.
General Procedures

To prevent the artificial oxidation during sample handling, samples were always
kept under argon. All buffers were treated with chelex-100 resin (Bio-Rad, Hercules, CA)
to remove residual amount of transition metal ions. The glassware was treated with
DTPA, rinsed with chelex-100 resin treated water, and baked at 500o C overnight prior to
use.
Desalting and Delipidation

The quantity of 20 µl serum or 600 µg tissue homogenate was spiked with DTPA
(final concentration100 μM) and adjusted to 500 μl with Chelex-resin treated water.
Ice-cold methanol (1.5 ml) was added and followed by diethyl ether (4 ml, water
saturated). The resulting solution was gently vortexed and incubated in an ice-bath for 20
minutes. The suspension was spun down at ~ 4000 rpm for 20 minutes. The supernatant
was discarded and the protein pellet was dried under nitrogen. Desalting and delipidation
was repeated again using the procedure above without DTPA supplementation.
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Protein Hydrolysis

The protein or tissue residue was dried under nitrogen piror to addition of
isotopically labeled internal standard cocktail.

The sample was then hydrolyzed at

110 °C for 20 hours in 0.5 ml methane sulfonic acid (MSA, 4 N) with 1% phenol and
0.3% benzoic acid supplement.
Solid Phase Extraction

Protein hydrolysates were diluted to 2 ml with Chelex-treated water and passed
over a C18 SPE column (500 mg, Supelco Inc., Bellefonte, PA). The column was
pretreated with 6ml methanol, rinsed with 6ml PB buffer (50 mM, pH 7.0, 100 μM
DTPA), followed by 6ml Chelex-treated water and equilibrated with 6 ml 0.1% TFA
water. After 2 x 2 ml of 0.1% TFA water wash, the amino acids were eluted with 2 ml
30% methanol in water containing 0.1% TFA. The samples were dried under speed vac
and re-dissolved in 120 μl chelex-treated water before analysis by mass spectrometer.
Instrumentation

Amino acids were quantified by stable isotope dilution LC-MS/MS. Each 60 μl
sample was analyzed on a Quattro Ultima mass spectrometer (Waters, Altrincham, U.K.)
interfaced with a Waters 2690 Separation Module HPLC system (Waters, Milford, MA,
USA). The source temperature was set at 250 °C. The cone and capillary voltages were
optimized at 30 V and 5 KV respectively. The collision energy was set to 15 eV with a
dwell time of 100 ms for each analyte.
The positively charged molecules were selected by mass-charge ratios and
focused in the collision chamber containing argon gas. The multiple-reaction monitoring
(MRM) transitions were used to detect oxidized tyrosine species and their precursors,
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tyrosine and phenylalaine, respecitvely. Each distinct parent-daughter transition was
detected by triple quadruple analyzer. The molecular ions of 3-BrTyr (M+) in positive
mode are m/z 260 [79 Br], 262 [81Br]. The product ion of 3-BrTyr include m/z 243 ([79Br]
M+ -NH3), 245 ([81Br] M+ -NH3), 214 ([79Br] M+ -CO2H2), and 216 ([81Br] M+ -CO2H2).
The parent-daughter transition 260 Æ 214 was used to quantify 3- Br Tyr. Similarly, the
transitions of 218 Æ 172, 361 Æ 315, 227 Æ 181 and 166 Æ 120 were used to quantify
3-ClTyr, di Tyr, 3-NO2 Tyr and phenylalanine respectively. Tyr, m-Tyr and o-Tyr use
same parent-daughter transition 182 Æ 136, with different retention times.
A Prodigy ODS 18 column (150 x 2 mm, 5 μm resin, Phenomenex, Torrance, CA,
USA) was used to separate amino acids at a flow rate of 0.2 ml/min. The column was
equilibrated with solvent A (0.2% formic acid in water) first. Then the analytes were
separated by a stepped linear gradient with solvent B (0.2% formic acid in acetonitrile) as
follow: 0% solvent B was held for 2 min, followed by a linear change from 0% B to 18%
B over 18 min, then hold at 80% B in next 2 min. The gradient was then kept at 80% B
for 4 min before return to 0% solvent B.
Statistical Analysis

Data are presented as mean ± SD. The statistic studies were performed using
SPSS version 11.0 (SPSS. Inc. Chicago, IL). The significance level was set at 95%.
5.3

Results

Oxidized Tyrosine Species in Nasal Mucosa in Normal Subjects

Amino acids isolated from acid hydrolysates of nasal mucosa were analyzed by
LC-MS/MS as described in experimental procedures. The identity of each authentic
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oxidized tyrosine was confirmed by the corresponding isotopically labeled internal
standard possessing identical retention time (Figure. 5.2).
Elevated o-Tyr, 3-BrTyr, and 3-ClTyr in Healthy Nasal Mucosa

To explore the mechanisms of leukocyte-catalyzed oxidative damage in healthy
sinonasal mucosa, the peripheral serum level of each oxidized tyrosine species and the
corresponding sinonasal tissue level were compared. In normal subjects, protein-bound
3-BrTyr level was significantly elevated in sinonasal tissue compared with that in serum
(556.9 µmol/mol vs. 40.0 µmol/mol, p<0.01). Levels of protein-bound tissue o-Tyr and
3-ClTyr in tissue were also observed (o-Tyr, 394.0 µmol/mol vs. 190.1 µmol/mol, p<0.05;
3-ClTyr/Tyr, 10.9 µmol/mol vs 5.3 µmol/mol, p<0.05). No other significant differences
between systemic and local levels of m-Tyr and diTyr were noted in healthy volunteers,
although there were trends toward higher levels in nasal mucosa (Figure. 5.3A).
Elevated m-Tyr, o-Tyr, di Tyr, 3-BrTyr, and 3-NO2Tyr in Nasal Mucosa from RS
Patients

In RS subjects, levels of m-Tyr, o-Tyr, di Tyr, 3-BrTyr and 3-NO2Tyr were all
elevated in sinonasal tissue compared with serum (m-Tyr, 131.4 µmol/mol vs. 88.4
µmol/mol, p< 0.01; o-Tyr, 458.0 µmol/mol vs. 213.5 µmol/mol, p< 0.001; diTyr, 5449.9
µmol/mol vs. 536.0 µmol/mol, p< 0.001; 3-BrTyr, 897.5 µmol/mol vs. 35.1 µmol/mol,
p< 0.001; 3-NO2Tyr, 43.9 µmol/mol vs. 17.6 µmol/mol, , p< 0.05) (Figure 5.3 B).
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Figure 5. 2

Chromatograph of Oxidized Tyrosine Species in Nasal Tissue

Specimen from a Rhinosinusitis Patient

Nasal tissue specimen was obtained from a RS patient and prepared as described
in Experimental Procedures. m-Tyr, o-Tyr (MRM: 182 Æ 136), diTyr (361 Æ 315),
ClTyr (218 Æ 172) and NO2Tyr (227Æ 181) were quantified by the corresponding
isotope internal standard, [13C6] m-Tyr, o-Tyr (MRM: 188 Æ 142), [13C12] diTyr (373 Æ
327), [13C6] ClTyr (224 Æ 178) and [13C6] NO2Tyr (233Æ 187) and [13C6] BrTyr (266Æ
220).
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Figure 5. 3

Sinonasal Tissue and Peripheral Serum Levels of m-Tyr, o-Tyr, 3-

BrTyr, 3-ClTyr, 3NO2Tyr and di Tyr

Panel A, comparisons of tissue and serum levels oxidized tyrosine species from
control subjects (n=10). The levels of o-Tyr, 3-BrTyr and3-ClTyr in sinonasal tissue
were significantly elevated. Panel B, comparisions of tissue and serum levels oxidized
tyrosine species from RS patients (n= 42). Sinonasal levels of m-Tyr, o-Tyr, 3-BrTyr, 3NO2Tyr and di Tyr were significantly elvelated. Data represent the mean ±SD.
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Sgnificantly Elevated Bromination and Tyrosylation in RS Patients Compare to
Those in Healthy Controls

To understand the mechanism of oxidative modification in nasal mucosa, the
tissue/serum ratio (T/S ratio) of each oxidized tyrosine species was calculated to
normalize individual differences. T/S ratios greater than one were noted for all analytes
indicating an elevated oxidative stress in sinonasal tissue. TheT/S ratios in RS patients
were significant greater than corresponding T/S ratios in control subjects (T/S ratio (mean,
μmol/mol/ μmol/mol), 3-BrTyr, RS, 27.0, control, 15.5, p<0.005; diTyr, RS, 18.4, control,

4.9, p< 0.05) (Figure. 5.4.). However, the T/S ratio for m-Tyr, o-Tyr, 3-ClTyr and 3NO2Tyr was similar in RS patients and controls (T/S ratio (mean, μmol/mol/ μmol/mol),
m-Tyr, control, 1.8, RS, 1.7, p=0.90; o-Tyr, control, 2.2, RS, 2.3, p= 0.79; 3-ClTyr,
control, 3.4, RS, 3.0, p=0.72; NO2Tyr, Control, 2.9, RS, 2.8, p= 0.94.).

167

Figure 5. 4

Bromination and Tyrosylation Were Significantly Increased in RS

Patients Compared with Control Subjects

The tissue/serum ratio of each oxidized tyrosine was calculated to normalize
individual differences. Elevated bromination and tyrosylation were significantly
increased in RS patients compared to those in controls (3-BrTyr T/S ratio, RS, 27.0± 11.6,
control, 15.5± 8.1, p< 0.005; di Tyr T/S ratio, RS, 18.4± 25.8, control, 4.9 ± 7.8, p< 0.05).
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5.4

Discussion

Human eosinophils produce reactive brominating species which can serve as
oxidants to participate host defense and may also cause host tissue damage 8, 20. Previous
in vitro data have demonstrated that peroxidases can utilize physiological levels of

halides or pseudohalides as co-substrates to generate reactive hypohalous acid even in the
presence of multiple competing co-substrates

17

.

Eosinophil activation and induced

oxidative modification were observed in numerous biological matrixes. Recent studies
found that significantly elevated protein-bound 3-BrY was recovered in sputum,
bronchoalveolar lavage fluid (BAL) in asthmatic patients compared to the healthy
controls

20, 31

. Elevated serum eosinophil is the hallmark of a chronic inflammatory in

rhinosinusitis patients

2, 5

.

In the current study, the tissue levels of 3-BrTyr were

significantly elevated in RS patients compared to that in control group (3-BrTyr, RS
(n=42) vs. Control (n=10), 871.1 µmol/mol vs. 556.9 µmol/mol, p< 0.05). However, half
of RS patients (n= 21) had asthmatic symptoms. Therefore, the potential impact of
asthma on protein oxidative damage in nasal tissue was investigated.

Significantly

elevated 3-BrTyr was detected in nasal mucosa in RS patients with or without asthmatic
symptom compared with control groups (3-BrTyr (µmol/mol), RS with asthma vs.
control, 861 vs.556.9, p< 0.05; RS without asthma, 881 vs.Control, 556.9, p< 0.05). But
there was no significant different in 3-BrTyr in nasal mucosa between RS patients with or
without asthma (3-BrTyr (µmol/mol), RS with asthma, 861 vs. RS without asthma, 881,
p= 0.856). The present study strongly suggests that asthmatic inflammation has no
significant impact on the augment of bromination in nasal mucosa in RS patients. Thus
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the elevation of 3-BrTyr levels supports activation of eosinophils in RS pathophysiology.
In this way, EPO-catalyzed oxidation may play central roles in fighting pathogens and
inadvertently in inducing non-specific host tissue oxidation.
This report describes both nasal mucosal tissue and serum levels of a panel of
oxidized tyrosine species in healthy control subjects as well as RS patients. Even in
healthy controls, tissue levels of o-Tyr, 3-ClTyr and 3-BrTyr were significantly higher
than the corresponding serum levels. Thus, under physiological conditions, nasal mucosa
serves as a sanctuary site for oxidative stress, as measured by dramatic elevations of
oxidized tyrosine residues in nasal mucosa from healthy subjects. The presence of
evidence of oxidative stress in health nasal mucosa is not surprising in light of the barrier
function provided by the nasal mucosa. The nasal cavity serves as a ‘trap’ for inhaled
micro-organisms and particulate matter. Removal of this foreign material occurs through
the active transport of mucus in the process of mucociliary clearance. Surveillance
provided by the immune system also occurs in the interface provided by the mucosa.
Since peroxidases released by inflammatory cells play an important role in the
inactivation of invasive micro-organisms and particulate matter, evidence of their activity
in healthy mucosa, where normal clearance of these non-self antigens is an active (and
successful) process that should be expected.
In RS patients, m-Tyr, o-Tyr, 3-BrTyr, diTyr and 3-NO2Tyr were all elevated in
nasal tissue compared with that in serum, suggesting a more generalized elevation of
oxidative stress in the tissues. This more generalized elevation of the oxidative stress in
sinonasal mucosa in RS patients probably reflects the underlying RS disease process of
inflammatory infiltration of the sinonasal mucosa.
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To further investigate the involvement of each distinct oxidative pathway in nasal
inflammation, RS patients were divided into two subgroups, allergic rhinosinusitis (ARS,
n=17) and nonallergic rhinosinusitis (NARS, n=25). Sinonasal tissue 3-BrTyr level was
significantly increased in NARS patients compared with controls (3-BrTyr (µmol/mol),
NARS, 927.7 vs. Control, 556.9, p <0.05). Sinonasal tissue levels of 3-BrTyr were
elevated but not reach statistic significant in the ARS and control groups (3-BrTyr
(µmol/mol), ARS, 787.8 vs. Control, 556.9, p =0.11), and no significant differences in
sinonasal tissue 3-BrTyr levels in NARS and ARS were noted (3-BrTyr (µmol/mol),
NARS, 927.7 vs. Control 787.8, p =0.20) (Figure 5.5 A.). In addition, sinonasal tissue
di-Tyr was significantly increased in ARS patients compared with control subjects
(di Tyr (µmol/mol), ARS, 5753.0 vs. Control, 2028.3, p <0.05). Sinonasal tissue levels
of di-Tyr were elevated but not statistic significant in the NARS and control groups (di
Tyr (µmol/mol), NARS, 4970.9 µmol/mol vs. Control, 2028.3, p =0.08), and no
significant differences in sinonasal tissue di Tyr levels in ARS and NARS were noted (di
Tyr (µmol/mol), ARS, 5753.0 vs. NARS, 4970.9, p =0.72). (Figure 5.5B.). Since the
mechanisms for nonallergic and allergic inflammation are often considered distinct, the
failure to identify many differences between allergic and nonallergic RS is surprising.
Perhaps, enhanced oxidative stress is a common feature of RS associated with allergic
and nonallergic inflammatory mechanisms.
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Figure 5. 5
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Rhinosinusitis (NARS) and Allergic Rhinosinusitis (ARS) Compared with Control

A, tissue 3-BrTyr levels in control (n=10), ARS (n=17) and NARS (n=25) were
compared. Significantly elevated sinonasal tissue 3-BrTyr levels were only observed in
NARS compared to control (NARS, 927.7 µmol/mol vs. Control, 556.9 µmol/mol,
p <0.05). In panel B, tissue levels of di-Tyr in control, ARS and NARS subjects were
compared. Significantly elevated tissue level diTyr were observed in ARS patients
compared to controls (ARS, 5753.0 µmol/mol vs. Control, 2028.3 µmol/mol, p <0.05).
No other significant differences were observed between ARS vs. Control and NARS vs.
ARS.
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Our previous study indicated that systemic level of protein-bound nitrotyrosine
declined in response to the treatment of with statins

32

. The primary design of current

study was not focused on the impact of anti-inflammation action of steroid on the
observed levels of oxidative markers. But due to general steroid usages in RS patients is
about 70%, it may have certain impact on reducing eosinophils, neutrophils and may
modulate the observed levels of bromination at serum and tissue level. Therefore the
serum level of 3-BrTyr was compared between RS patients with or without steroid usage.
No significant difference in bromination was observed between RS patients with or
without steroid usage at serum level (3-BrTyr (µmol/mol), RS with steroid vs. RS
without steroid, 35.1 vs. 34.9, p= 0.95). However, in RS patients with tissue level 3BrTyr ≤ 658.6 µmol/mol (T1), 64% of them had steroid treatment. The steroid usage was
increased to 86% when RS patients with tissue levels of 3-BrTyr were greater than
1027.9 µmol/mol (T3). The trend did not reach statistic significant due to limit study
number, various brands steroid usages. In addition, without the oxidative profile prior to
treatment, the therapeutic impact of steroid at inflammation site is still unsolved. Future
study the correlation of oxidative modification in nasal mucosa in response to steroid,
especially nasal steroid treatment is necessary.
5.5

Conclusion

The elevations of oxidized tyrosine species in healthy nasal mucosa (compared
with corresponding serum levels) suggests that oxidative stress occurs in nasal tissue
under normal physiologic conditions. Furthermore, detection of end products of oxidative
metabolism in normal tissue supports the concept that nasal mucosa is a sanctuary site for
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host defenses against potentially pathogenic micro-organisms and other foreign antigens.
RS patients show an even higher level of oxidative stress in nasal tissue. Thus, activation
of oxidative pathways may contribute to RS pathogenesis.

5.6
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